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1. Introduction 
Paroxysmal nocturnal hemoglobinuria (PNH) is a complex hematological disorder resulting 
in a quite unique clinical syndrome. In fact, the typical clinical presentation encompasses 
three distinct hematological manifestations, i.e., hemolytic anemia, bone marrow failure and 
thrombophilia (Dunn et al 2000; Parker & Ware 2003; Notaro & Luzzatto 2003). Thus, the 
term PNH covers only one feature of the disease – the one that is the most evident to 
patients, even if it does not reveal the actual clinical and pathophysiological complexity of 
the disease. The first extensive description of PNH was made by Dr. Strübing in 1882, 
although some cases could be identified even in older reports (maybe the first one dates 
back to 1678 by Dr. Schmidt from Gdanks). Remarkably, Dr. Strübing recognized the 
uniqueness of the clinical syndrome (hemolytic anemia with possible thrombosis), 
anticipating some of the pathophysiological implications that were unraveled decades later. 
In fact, he hypothesized that hemoglobinuria was due to “red blood cells which dissolve into the 
vessels” (corresponding to intravascular hemolysis in current terminology), possibly 
secondary to a “disordered blood production” of erythrocytes which are “abnormally sensitive” 
to acidification (namely, the production of blood cells with the aberrant PNH phenotype, 
that makes them susceptible to complement-mediated lysis) (Crosby 1951). However, it was 
with Marchiafava and Nazari (Marchiafava & Nazari 1911) in 1911 that the disease was 
recognized as a distinct medical entity, characterized by “chronic hemolytic anemia with 
perpetual hemosiderinuria”, subsequently known as the Marchiafava-Micheli syndrome (Micheli 
1928); the current name “paroxysmal nocturnal hemoglobinuria” was eventually coined by Dr. 
Enneking in 1928 (Enneking 1928). In the last century, a number of reports on PNH were 
subsequently published because the puzzling nature of the disease has intrigued 
generations of investigators; however, PNH remained a mystery until the 1980s, when most 
of its pathophysiology was progressively elucidated, first with the description of the 
molecular defect of PNH cells, and then with the identification of the underlying genetic 
defect. By that time it was already known that PNH erythrocytes are exquisitely sensitive to 
lysis upon complement activation, both in vivo and in vitro. Thus, the observation that PNH 
cells lack from their surface some complement regulators, all included in a specific class of 
membrane-bound proteins (the so-called glycosyl phosphatidyl-inositol (GPI)-anchored 
proteins [GPI-APs]), clearly explained the reason for such sensitivity. Thereafter, the 
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biochemical pathway accounting for GPI-AP surface expression was described, as well as its 
impairment in PNH cells. Finally, the genetic lesion leading to the aberrant phenotype was 
identified in distinct mutations in the phosphatidyl-inositol glycan class A (PIG-A) gene. This 
formally demonstrated that PNH is a clonal hematological disorder characterized by the 
expansion of abnormal (GPI-AP deficient, PIG-A mutated) hematopoietic stem cells (HSCs) 
carrying an intrinsic defect, that accounts for the clinical phenoptype of the disease. 
Nowadays most pathophysiological events occurring in PNH patients have been 
extensively described, even if definitive explanations for some disease manifestations (i.e., 
thromboembolic events) are still elusive. In the last few years, insights into the field 
pertain to the new treatment strategies that have drastically changed the management and 
clinical outcome of PNH patients. In fact, the availability of an inhibitor of the 
complement cascade – the actual effector mechanism of hemolysis in PNH – has led to the 
first etiological treatment for PNH, which seems to have a superb impact on the natural 
history of the disease.  
2. Epidemiology 
PNH is a rare acquired disease, with a worldwide prevalence estimated in the range of 1-5 
cases per million (Rosse 1996; Orphanet 2004) regardless of the ethnicity; however, given the 
rarity of the disease and possible reporting biases, its incidence and prevalence remain 
largely unknown. Indeed, most reports deal with retrospective data, but formal 
epidemiological studies are lacking. A recent analysis from a well-defined geographical area 
(Hill et al 2006c) suggests that the actual incidence could be higher than previously reported, 
in the range of about 1.3/1,000,000/year, leading to a prevalence of about 15 cases per 
million in a 15 year observation period; however, these data may suffer from biases due to 
referral center, as well as to inclusion criteria (Parker et al 2005; De Latour et al 2008) In fact, 
a higher incidence might reflect the inclusion of patients with subclinical PNH, who have 
not been included in previous studies. In additional, geographical variations in PNH 
incidence should be considered; for instance, an increased prevalence is reported in some 
regions which also harbor higher incidence of aplastic anemia (e.g., Thailand and some 
other Asian countries) (Pramoonjago et al 1999). A multi-national prospective PNH registry 
is currently ongoing, and possibly will provide more definitive data on the actual incidence 
and prevalence of PNH in different geographical areas (Muus et al 2010). The incidence of 
PNH is similar in both genders, and most patients are diagnosed in their middle age (third 
or fourth decades), although cases have been reported in adolescents, children and even the 
elderly (De Latour et al 2008; Ware et al 1991). 
3. Genetic basis 
3.1 The GPI anchor and the PIG-A gene  
The hallmark of PNH is hemolytic anemia secondary to the intrinsic susceptibility of 
affected red cells to complement activation (Ham & Dingle 1939; Rosse & Dacie 1966); thus, 
the presence of intrinsically abnormal blood cells is the cause of the disease phenotype. 
However, in PNH patients not all blood cells are affected, as they in fact present a 
mosaicism of normal and abnormal blood cells; therefore, a putative genetic cause was 
unlikely to be inherited or transmitted to the progeny. The clonal origin of PNH 
hematopoiesis was first demonstrated in 1970 by Dr. Luzzatto’s group, who showed that, in  
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patients heterozygous for the glucose-6-phosphate-dehydrogenase (G6PD), affected red 
blood cells (RBCs) all share the same G6PD allele (which, on the other hand, is not involved 
in pathophysiology of the disease per se) (Oni et al 1970). Subsequently, the biochemical 
defect of PNH cells was identified in a specific molecular abnormality, consisting in the 
bizarre lack of several proteins from the cell surface. This peculiar defect was first described 
in the 1980s (Kunstling & Rosse 1969; Nicholson-Weller et al 1983; Selvaraj et al 1988), and 
rapidly became the hallmark of PNH, although its relationship with the pathophysiology of 
the disease remained obscure at that time. Notably, this abnormal phenotype pertained not 
only to erythrocytes, rather it included myeloid and megakaryocytic lineages too, 
suggesting that it derived from either multi-potent hematopoietic progenitors or even 
hematopoietic stem cells (Kinoshita et al 1985). Focusing on the underlying intrinsic 
abnormality rather than on the consequences of individual protein deficiency (which 
accounts for the susceptibility to hemolysis, as discussed later on), it became clear that all 
the proteins missing from the PNH cell surface shared a common mechanism responsible 
for their attachment to the cell membrane (Medof et al 1987). This is a specific glycolipid 
structure named glycosyl-phosphatidyl inositol (GPI) anchor (Mahoney et al 1992). The 
functional implications of the GPI-anchoring of proteins are not completely understood; 
they include ease of assemblage and shedding, lateral mobility, capping, involvement in 
endo-, exo-, and potocytosis (a clathrin-independent form of endocytosis and recycling). The 
strongest evidence that this type of membrane anchoring is important in cell biology is its 
high conservation among eukaryotic cells; indeed, it is found even in yeast and 
trypanosome. In 1993, using complementation of GPI-anchored protein deficient cell lines 
and expression cloning, Kinoshita and colleagues first isolated the cDNA of the PIG-A gene 
(Takeda et al 1993; Miyata et al 1993). PIG-A is a housekeeping gene located on the short 
arm of the X chromosome (Xp22.1); the organization of the genomic gene was described in 
1994 (Bessler et al 1994). The PIG-A gene, in combination with at least two other proteins, 
encodes an enzyme essential to transfer N-acetyl glucosamine to phosphatidyl inositol; this 
is the very first step of the GPI-anchor biosynthesis (Armostrong et al 1992; Hirose et al 1992; 
Takahashi et al 1993). GPI-deficient cell lines showing defects in any of the various 
metabolic steps have been produced by experimental mutagenesis (Kinoshita et al 1995); 
however, the study of PNH has shown, at the very beginning surprisingly, that the same 
early step is impaired in all patients, and all patients have a mutation in the PIG-A gene 
(Takeda et al 1993, Luzzatto et al 1997, Nafa et al 1995). The present explanation for this 
finding is that among the various genes involved in the GPI-anchor synthesis, PIG-A may be 
the only one that is X-linked (Almeida et al 2009). As a consequence, a single mutation in 
that gene will produce an abnormal cell in either sex: males have only one allele and females 
have only one functional allele (as result of X-chromosome inactivation). Although females 
have two PIG-A alleles, only half of the mutation will occur in the functional X; thus, the risk 
of having the disease is the same in both genders. Since a defect causing a metabolic block is 
generally recessive, it is very unlikely (although not impossible) that a double mutation 
targeting both alleles of an autosomal gene in the same cell may occur in vivo. In keeping 
with this assumption, quite recently two kindreds harboring a mutation in the PIG-M gene 
were described (hence, with the genetic lesion inherited, not acquired). Indeed, all affected 
members did not develop PNH, but presented a quite distinct clinical syndrome 
characterized by a partial GPI deficiency associated with a propensity to thrombosis and 
seizures, in the absence of significant hemolysis (Almeida et al 2006).  
www.intechopen.com
 
Anemia 
 
334 
3.2 PIG-A mutations in PNH 
Direct sequencing of the PIG-A gene has demonstrated distinct mutations in all PNH 
patients (Luzzatto et al 2000; Nishimura et al 1999); in most cases, each patient has a single 
mutation (even if distinct PIG-A mutated clones may co-exist in some patients) and 
mutations are unique to each patient (private mutations). These mutations can be found in 
all blood lineages, consistent with a genetic lesion occurring in hematopoietic stem cell(s) 
(Takeda et al 1993; Endo et al 1995). All types of mutations have been observed (Nafa et al 
1995; Nafa et al 1998): small deletions or insertions producing frameshift (the most 
frequent), nucleotide substitutions resulting in stop codon, large deletions, missense 
mutations causing amino acids substitutions or new sites for alternative splicing. No 
particular clustering of mutations has emerged, even if most of the mutations occur in exon 
2, probably because it is the largest. If we compare the type of mutations found in PNH with 
those found in G6PD deficiency -- another (this time inherited) X-linked disorder of a 
housekeeping gene -- a clear discrepancy is evident. In PNH, a vast majority of mutations 
have extremely severe functional consequences, (i.e., production of truncated proteins, 
leading to a complete GPI deficiency – the PNH type III phenotype), whereas missense 
mutations are rare (usually resulting in the PNH type II phenotype); in G6PD deficiency 
almost all mutations are missense, leading to single amino acid substitutions with conserved 
(although possibly altered) function. Two considerations may be relevant to this 
discrepancy: i. in inherited disorders, mutations in a housekeeping gene may be lethal, and 
thus have been selected to allow residual functional activity; by contrast, null mutations can 
be seen if they are somatically acquired, because they do not affect organ development and 
pertains only to a small fraction of somatic cells, which may survive albeit with some 
functional abnormality; ii. if missense mutations in PNH are rare, it means that the gene 
must be seriously damaged for leading to a clonal expansion. Indeed, the rare missense 
mutations found in PNH patients are associated with a marked reduction of GPI-linked 
proteins, indicating that they usually have affected either mRNA stability or protein 
function, or both. Remarkably, different types of mutations may account for different cell 
phenotypes in PNH patients, especially when the erythrocytes are considered. In fact, RBCs 
harboring a mutation leading to the complete inactivation of the PIG-A gene product will 
unequivocally show a complete deficiency of all GPI-APs from their surface (the so-called 
PNH type III phenotype). In contrast, mutations leading to partial inactivation of the PIG-A 
gene (for instance missence mutations) may lead to a partial deficiency of GPI-APs, known 
as the PNH type II phenotype. Of note, this biochemical finding has direct functional 
consequences; in fact, as discussed later on, type II and type III erythrocytes have a quite 
distinct susceptibility to complement-mediated lysis (Rosse & Dacie 1966). Quite 
surprisingly, some PNH patients may harbor at the same time type II and type III cells, 
suggesting that distinct PIG-A mutated HSCs may expand concomitantly (Endo et al 1995; 
Nafa et al 1998). Indeed, even phenotypically identical PNH cells may carry distinct PIG-A 
genotypes (Endo et al 1995, Nishimura et al 1997), suggesting that the functional phenotype 
rather than the specific genetic defect may play a major role in the development of the 
disease (Luzzatto et al 1997), as discussed below. 
4. Pathophysiology 
4.1 The dual pathophysiology theory 
PNH develops through a somatic mutation in the PIG-A gene occurring in HSC(s), which 
originate progeny mature blood cells uniquely lacking of all GPI-APs from their surface. 
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PNH is therefore an acquired genetic blood disorder, that cannot be transmitted to the 
progeny; however, the PIG-A mutation is likely insufficient to cause the disease and 
additional events are thought to be involved (Rotoli & Luzzatto 1989).  
4.1.1 The PIG-A mutation is not sufficient for the development of clinical PNH 
A number of observations support the idea that the PIG-A mutation itself is necessary, but 
not sufficient to cause PNH. In fact, the expansion of PNH cells over normal hematopoiesis 
remains a key step to develop the disease phenotype. These observations include both 
findings from tentative animal models of PNH, as well as findings from human individuals, 
with or without PNH. 
Murine models of PNH. In order to explore experimentally the causal relationship between 
the PIG-A mutation and the development of PNH, murine models have been generated in 
the last few years to recapitulate human PNH (Rosti 2002). Initially, a complete knockout 
animal has been attempted, but it could not be produced due to fetal loss, demonstrating 
that pig-a is necessary for embryogenesis (Kawagoe et al 1996). Thus, a different strategy 
was devised, aiming to inactivate the mouse pig-a gene directly in embryonic stem (ES) cells, 
using the conventional knock-out gene targeting technique. Preliminary in vitro studies 
demonstrated that pig-a deficient ES cells were able to differentiate into mature cells of 
various hematopoietic lineages, thus showing that pig-a is not necessary for the 
differentiation and maturation of hematopoietic progenitors (Rosti et al 1997).  However, 
when this approach was challenged in vivo, using chimeras obtained by inserting pig-a 
knocked out ES cells in early embryonic development, only a few chimeras survived 
(pointing out, once again, the pivotal role of the GPI-anchor for embryonic development), 
showing a low proportion of GPI-deficient blood cells at birth, which subsequently 
decreased with aging (Tremml et al 1999). These data support the theory that there was no 
absolute growth advantage for pig-a mutated cells as compared to normal cells coexisting in 
the same organism. Notably, the generation of a mouse model showing in vivo expansion of 
pig-a mutated hematopoiesis, thus better mimicking the human PNH disease, required a 
more sophisticated experimental approach (Keller et al 2001; Jasinski et al 2001). This 
included a conditional inactivation of the murine pig-a gene implemented using Cre 
recombinase and its specific recombination sites loxP; when the Cre/loxP system was 
targeted to the hematopoietic stem cells or the erythroid/megakaryocytic lineage using 
tissue-specific c-FES and GATA-1 regulatory sequences, respectively, the generation of mice 
having almost 100% of red cells with the PNH phenotype was obtained. However, even 
these mice do not really mimic the disease phenotype seen in humans, because PNH 
hematopoiesis tends to decrease over time (Jasinski et al 2001). Indeed, the conclusion from 
murine models is that the pig-a mutation is not sufficient itself to sustain the expansion of 
PNH-like hematopoiesis over time, suggesting the presence of additional causal factors.  
PIG-A mutations in human individuals. PIG-A mutation may be identified in affected cells 
from all PNH patients, demonstrating a clear etiological role in the development of PNH. 
However, it is not true that all individuals who undergo inactivating mutations in the PIG-A 
gene develop clinical PNH. In fact, it has been shown that a few blood cells harboring the 
PNH phenotype (namely, a complete or partial deficiency in all GPI-APs) may be detected 
even in normal individuals, at a frequency of 10 to 50 cells per million (Araten et al 1999). 
This was possible thanks to an ultra-sensitive flow cytometry analysis (see above, diagnosis 
of PNH) of large numbers of circulating granulocytes or erythrocytes obtained from healthy 
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subjects. When these phenotypically abnormal cells were selected and studied at the genetic 
level, they revealed themselves to be clonal, and to carry specific PIG-A mutations (as 
demonstrated by a nested PCR technique) undistinguishable from those identified in PNH 
patients (Araten et al 1999). This clearly demonstrated that, in vivo, a PIG-A mutation was 
not sufficient to cause the disease, for at least two different reasons. First, to sustain clonal 
expansion, such mutations have to occur in multipotent HSC, while in most cases they 
statistically could pertain to cells without self-renewal capability, such as differentiated 
blood cells or committed hematopoietic progenitors. Second, a PIG-A mutation, even when 
occurring in a HSC, could simply confers a biological phenotype (the GPI deficiency) that 
requires additional, PIG-A-independent, conditions for further clonal expansion leading to 
the disease. The latter view is also supported by the observation that, at least in some 
patients, PNH hematopoiesis may include more than one abnormal clone. This was initially 
postulated based on the differential susceptibility of erythrocyte population to complement 
lysis (Rosse & Dacie 1966; Rotoli et al 1984), as subsequently demonstrated by flow 
cytometry (van der Schoot et al 1990), and finally confirmed by PIG-A sequencing (Endo et 
al 1996; Nishimura et al 1997)). In keeping, the expansion of distinct clones carrying the 
same, albeit molecularly heterogeneous, functional defect seems to suggest an expansion 
based on non-stochastic processes, such as selection, rather than a random process. This is 
also supported by the observation that relapse of PNH may be sustained by clones 
harboring PIG-A mutations different from those identified at diagnosis (Nafa et al 1998).  
4.1.2 Clonal expansion of the PIG-A mutated clone(s) and development of clinical PNH 
This background raised the hypothesis of a dual pathophysiology for PNH: the PIG-A 
mutation is not sufficient to cause the disease, and requires a second, independent event 
(Rotoli & Luzzatto 1989). This theory is also known as the “relative advantage” (Luzzatto et 
al 1997) or “escape” theory (Young & Maciejewski 2000). According to this view, a mutation 
in the PIG-A gene might be a fairly common phenomenon, with no major biological 
consequences, because in physiological conditions the mutated cell has no reason for 
expanding in the presence of a vast majority of normal cells. In fact, no intrinsic proliferative 
advantage has been demonstrated in PNH hematopoietic progenitors in comparison to 
normal ones (Araten et al 2002). However, additional factors may alter this equilibrium, 
creating the conditions for the expansion of PNH clone(s), and possibly leading to the 
occurrence of a single PIG-A mutated stem cell sustaining hematopoiesis even for the rest of 
the patient’s life (Nishimura et al 2002; Nishimura et al 2004). The nature of such second 
event(s) can be of various origin, and distinct pathways -- not necessarily mutually exclusive 
-- have been postulated. 
An immune-mediated damage of hematopoiesis sparing PNH cells. The well-accepted theory of 
PNH pathophysiology claims that such second event is a change in the microenvironment of 
hematopoiesis, leading to the selective expansion of the PIG-A mutated cells. It is quite 
accepted that such external factor, which does not affect the intrinsic features of the PIG-A 
mutated cells, is an (auto)-immune attack against hematopoiesis. Several clinical and 
experimental observations support the presence of such auto-immune attack in PNH; they 
include the well-known clinical overlap between PNH and aplastic anemia (AA, which is in 
most cases immune-mediated) (Lewis & Dacie 1967), as well as the direct demonstration of 
immune abnormalities in PNH patients. All these observations are discussed later on in this 
chapter. Indeed, normal and PNH cells are not different in terms of growth or survival, but 
PNH cells could be spared by immune-mediated damage, finally resulting in a progressive 
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consumption of normal hematopoiesis, with relative expansion of PNH hematopoiesis 
(Rotoli & Luzzatto 1989; Luzzatto et al 1997; Young & Maciejewski 2000). This was 
confirmed by gene expression profiling performed in normal and PNH HSCs: when CD34+ 
cells from PNH patients were separated according to the presence or absence of GPI-APs on 
their surface, distinct patterns of gene expression were identified. In fact, phenotypically 
normal (GPI-AP positive) CD34+ cells harbored diffuse abnormalities of their transcriptome, 
with over-expression of genes involved in apoptosis and immune activity, paralleling the 
findings seen in CD34+ cells of AA patients. By contrast, phenotypically abnormal PNH 
CD34+ (GPI-AP negative) showed a gene expression profiling closer to that obtained in 
CD34+ cells from healthy individuals (Chen et al 2005). Notably, normal and PNH CD34+ 
cells did not show any difference in the genes involved in growth or proliferation, rather 
suggesting the presence of sublethal extrinsic damage in phenotypically normal HSCs but 
not in their PIG-A mutated counterpart. Indeed, PNH cells ultimately expand as a result of a 
selective pressure that acts negatively on normal hematopoiesis; however, the molecular 
reasons underlying the “escape” still remain elusive. Contradictory data have been 
produced on a putative differential sensitivity to inhibitory stimuli between normal and 
PNH cells; susceptibility to apoptosis has been reported to be increased, normal or 
decreased in different models. It has been shown that human cell lines carrying the PIG-A 
mutation are less susceptible to NK-mediated killing compared to their normal counterpart 
(Nagakura et al 2002). In a more sophisticated model, GPI-deficient cells were not able to 
induce primary and secondary stimulation of both antigen-specific and alloreactive T cells, 
providing experimental support to the hypothesis that the PNH clone could inefficiently 
interact with the immune system (Murakami et al 2002). Indeed, the actual mechanisms 
causing the escape may include the absence of specific GPI-APs directly targeted by 
effector immune cells, or a protection due to the absence of important molecules involved 
in cell-cell interaction (e.g., accessory molecules). Alternatively, a broader impaired 
sensitivity to common effector mechanisms may be hypothesized, possibly due to the lack 
of GPI-APs or to non specific structural changes of the raft structure in the outer surface. 
Remarkably, the observation that patients with a B-cell lymphoproliferative disorder 
treated by alemtuzumab may develop expansion of GPI-deficient (PNH-like) T cells 
indirectly confirms the escape theory. Alemtuzumab is a monoclonal antibody that kills 
lymphocytes targeting the GPI-linked protein CD52; after treatment, CD52-negative 
lymphocytes may be found, which also lack all other GPI-APs. Once such lymphocytes 
are cloned, mutations in the PIG-A gene can be demonstrated; interestingly, the same 
mutation can be found also in a few cells from pre-treatment blood samples. In most cases 
these expansions are self-limiting and transient, and GPI-deficient T-cells gradually 
disappear after alemtuzumab discontinuation. Thus, this model elucidates most features 
of the PNH pathogenesis: the pre-existence of PIG-A mutated cells, their expansion only 
in the presence of a selective pressure negatively acting on normal cells (mutated cells are 
intrinsically resistant to alemtuzumab due to the absence of CD52), and the gradual 
disappearance of the mutated clone once the selective mechanism has been removed 
(Hertestein et al 2005). It has to be remarked that none of these alemtuzumab-treated 
patients developed PNH, because the expansion of GPI-AP deficient clones includes only 
mature lymphocytes and not multipotent HSCs (alemtuzumab does not kill HSC or 
hematopoietic progenitors, because CD52 expression is restricted to the lymphoid cells).  
Additional mutations conferring growing advantage. The selective advantage of the PIG-A 
mutated clone could also be explained by a second (or a pre-existing) mutation of the 
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aberrant clone, which confers an absolute growth advantage. The most striking evidence 
supporting this theory is the observation that a few PNH patients may harbor, in the PIG-A 
mutated clone, an additional concomitant genetic lesion in the chromosome 12. This lesion 
was identified in a mutation in the 3’ of the HMGA2 gene, which leads to HMGA2 over-
expression and subsequent proliferative advantage (Inoue et al 2006). However, this 
mutation has not been found in larger series of PNH patients, making the pathogenic role of 
this lesion questionable. Clonal dominance of the PNH clone may also be due to other, still 
unknown, additional mutation(s) of the PIG-A mutated cells, possibly secondary to an 
intrinsic genetic instability of the abnormal clone. However, recent data exclude that PIG-A 
mutated cells have any increase in genetic instability. In fact, using the PIG-A itself as 
sentinel gene, the intrinsic rate of somatic mutation in PNH cells did not differ from that of 
normal cells, and it was remarkable less than that of cells with known genetic instability (i.e., 
Fanconi Anemia cells) (Araten et al 2007). Thus, these data argue against the possibility that 
PNH can be due to either a pre-existing genetic instability favoring the PIG-A mutation, or 
to a genetic instability secondary to the PIG-A mutation itself, which could predispose to 
additional genetic events necessary for PNH development. This is also supported, in vivo, by 
the clinical observation that malignant evolution in PNH patients is extremely rare, even if 
possible (Krause 1983; Devine et al 1987a); karyotypic abnormalities can been found in a few 
PNH patients, but in most cases they are transient and do not lead to leukemic 
transformation (Araten et al 2001). Remarkably, both MDS and truly leukemic cells not 
necessarily come from the PIG-A mutated clone; in fact, even more frequently they arise 
from the non-PNH, normal, residual hematopoiesis (van Kamp et al 1994; Araten et al 2001). 
Thus, the malignant evolution seems not related to any intrinsic feature secondary to the 
PIG-A mutation, but rather to the underlying bone marrow disorder, possibly including 
even clonal dominance itself. 
The neutral evolution theory. More recently, a third possibility has been postulated, that even 
the expansion of the PIG-A mutated HSC could be a simple stochastic phenomenon, not 
requiring any additional event; this theory has been described as the “neutral evolution” 
hypothesis. According to the mathematic model provided by Dingli (Dingli et al 2008), 
given the stochastic nature of hematopoiesis (Notaro & Luzzatto et al 2010), a PIG-A 
mutation may randomly occur within the active HSCs pool, which in adults comprises 
about 400 cells, each replicating, on average, once per year. Subsequently, the expansion of 
the mutant clone may simply reflect the stochastic dominance of a few HSC, regardless of 
any functional feature (either absolute or conditional growth advantage), which may lead to 
a PNH clone size large enough to cause the disease. According to the authors, this model 
would fit the actual (expected) incidence of PNH (Hill et al 2006c). The chances that a single 
clone (even carrying a neutral mutation like the PIG-A) overcomes residual hematopoiesis 
increases with oligoclonal hematopoiesis, reconciling the model with the observation that 
clinical PNH mostly develop in patients with an underlying bone marrow failure.  
4.2 Hematopoiesis in PNH patients 
4.2.1 Marrow failure and PNH 
As discussed later on, anemia is a typical presentation of PNH; however, cytopenias 
involving other blood lineages are also common in PNH patients. Cytopenia in these 
patients is mainly due to impaired production by the bone marrow, as confirmed by the 
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reduction in hematopoietic progenitors assessed by culture assays. In fact, it has been 
demonstrated that bone marrow from PNH patients show a significant reduction in all 
lineage-committed progenitors (CFU-E, BFU-E, CFU-GM, CFU-GEMM) (Rotoli et al 1984; 
Maciejewski et al 1997) , as well as in stem cells/multi-potent progenitors (LTC-IC) 
(Maciejewski et al 1997). This was demonstrated in all PNH patients, regardless of their 
clinical presentation (see disease classification) (Parker et al 2005); namely, a subclinical 
marrow failure can be detected even in patients with hypercellular bone marrow. The 
functional impairment of the bone marrow may become clinically evident in a fraction of 
patients (at least one third), leading to mild cytopenia up to clinically significant bone 
marrow failure, seen as aplastic anemia (AA) (Lewis & Dacie 1967). In fact, many PNH 
patients may sooner or later develop frank aplastic anemia during the course of their disease 
(Hillmen et al 1995; Sociè et al 1996; De Latour et al 2008); conversely, AA patients may also 
develop PNH. Indeed, a substantial fraction of AA patients (up to 40%) may have detectable 
PNH clone (Nissen et al 1999; Mukhina et al 2001; Sugimori et al 2006; Scheinberg et al 
2010), in most cases not large enough to cause evident hemolysis; however, the size of the 
PNH clone may vary over time, possibly leading to clinical PNH. Thus, PNH and AA are 
closely embedded (Dameshek 1967), and should be considered as different presentations of 
the same disorder rather than independent conditions. Furthermore, regardless of its clinical 
presentation, PNH must be considered by definition a bone marrow disorder because of its 
impairment of hematopoiesis, which is both quantitative (clinical or subclinical) and 
qualitative (the aberrant phenotype stems from the PIG-A mutated HSC). To some extent, 
PNH could be considered an attempt of the body to prevent the development of AA by 
rescuing hematopoiesis with PNH cells (Rotoli & Luzzatto 1989); in fact, the PNH clone 
ensures some mature blood cells, even if it leads to specific consequences secondary to the 
abnormality of the PNH cells (i.e., hemolysis and thrombophilia). 
4.2.2 Immune derangement in PNH patients  
Given the clinical overlap between PNH and AA, it is reasonable to hypothesize that 
pathogenic mechanisms involved in AA may also play a pivotal role in PNH, representing 
the additional factor required for developing clinical PNH once a PIG-A mutation has 
occurred (without any specific chronologic order). The immunological mechanisms in 
idiopathic AA play a pivotal role in damaging the hematopoietic compartment, leading to 
HSC pool consumption or to functional impairment and subsequent pancytopenia (Young 
& Maciejewski 2000; Young et al 2006). A number of experimental observations supports the 
presence of an anti-hematopoiesis immune attack, although the target antigens are still 
undefined, as are the mechanisms leading to the breach in immune tolerance. Unknown 
triggers of autoimmunity induce a cellular immune response resulting in a preferential 
expansion of specific T cell clones that may damage the hematopoietic progenitors, directly 
or through indirect mechanisms, such as the production of inhibitory cytokines. Stem cell 
damage can be mediated by cytokine-transduced inhibition (mostly type I cytokines, such as 
interferon-Ǆ and tumor necrosis factor-), or by direct cell-mediated killing due to cytotoxic 
lymphocytes (CTLs) (reviewed in Young et al 2006). Such mechanisms, which may attack 
innocent bystander cells in addition to the primary target cells, ultimately result in 
apoptosis, the main key mechanism of HSC damage. Circulating and marrow CTLs have 
been demonstrated in vivo in AA patients, and their inhibitory effect on hematopoiesis has 
been documented in vitro (reviewed in Young et al 2006); this cellular immune response has 
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been dissected at the molecular level through the identification of in vivo-dominant T cell 
clonotypes, which are evidence of a pathogenic antigen-driven immune response (Risitano 
et al 2004). Since in PNH a similar antigen-driven immune response targeting marrow tissue 
may be postulated, investigators have evaluated the same pathways of the immune system 
for possible abnormalities. As for AA, evidence of immune derangement in PNH has been 
produced, mostly pointing out the pivotal role of cell-mediated immunity. In fact, 
oligoclonality of the T cell pool has been reported (Karadimitris et al 2000), and 
immunodominant pathogenic CTL clones may be detected in most PNH patients (Risitano 
et al 2004; Plasilova et al 2004). Notably, immunodominant T-cell clones identified in PNH 
patients may share highly homologous T-cell receptor beta (TCR-beta) sequences, and 
additional closely related sub-dominant T-cell clones may be identified, consistent with an 
antigen-driven public immune response (Gargiulo et al 2007). The observation that recurrent 
or highly homologous TCR-beta sequences may be identified regardless of the individual 
patient’s HLA background (in contrast with what is seen in AA) (Risitano et al 2004), may 
also suggest that a non-peptidic triggering antigen may be involved, possibly related to the 
GPI-anchor itself (Gargiulo et al 2007). Functionally, these pathogenic T cells harbor an 
effector, cytotoxic phenotype, characterized by expression of CD8 and CD57. These effector 
lymphocytes also show an imbalance in the expression of the activating and inhibitory surface 
receptors; in fact, they tend to over-express the activating isoforms of inhibiting superfamily 
receptors, which elicit a powerful cytolytic activity (Poggi et al 2005). Notably, in some PNH 
patients these CTL clonal populations may expand to represent a subclinical (Risitano et al 
2005) or even clinically meaningful LGL proliferations (Karadimitris et al 2001). 
4.3 Hemolysis in PNH patients 
4.3.1 The complement system  
The complement system is a key component of innate immunity, that has evolved to 
recognize both exogenous pathogenic microorganisms as well as injured self tissues, and to 
amplify adaptive immunity (Müller-Eberhard 1988; Holers 2008). The complement system 
encompasses distinct functional pathways with unique mechanisms of activation, which 
then all merge into a common final effector mechanism -- the cytolytic membrane attack 
complex (MAC). Thus, initiation of complement activation may occur along three different 
pathways – classical, alternative or lectin – which independently lead to activation of C3 and 
C5 convertases. While the classical and the lectin pathways require specific triggers to be 
activated, usually infectious agents, it has been known for decades that the complement 
alternative pathway (CAP) exhibits low-grade continuous activation due to spontaneous 
hydrolysis of C3 (the so-called tick-over phenomenon) (Pangburn et al 1981; Pangburn & 
Müller-Eberhard 1983). In addition, some components of the CAP constitute an 
amplification mechanism (the so called CAP amplification loop), which amplifies 
complement activation regardless of the specific pathway that initially generates the first 
C3b molecule. Fine mechanisms have evolved to control the complement system, including 
membrane-bound proteins (complement receptor 1 [CR1], membrane cofactor protein 
[MCP], and the membrane proteins CD55 and CD59) as well as fluid-phase components, 
including complement factor I (FI) and factor H (FH). Among these, CD55 and CD59 are of 
pivotal importance in PNH, given that they are normally expressed on blood cells through 
the GPI-anchor (Medof et al 1986). 
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4.3.2 Complement regulatory proteins and PNH erythrocytes 
CD55, also known as Decay Accelerating Factor (DAF), is a 70-kd protein first isolated in 
1969 (Hoffman 1969) and subsequently purified in 1982 (Nicholson-Weller et al 1982) which 
inhibits the formation and the stability of C3 convertase (both C3bBb and C4b2a) 
(Nicholson-Weller 1992). Historically, CD55 was the first complement regulator reported to 
be absent on PNH erythrocytes (Pangburn et al 1983(a); Pangburn et al 1983(b); Nicholson-
Weller et al 1983) possibly accounting for the increased susceptibility of PNH erythrocytes 
to complement mediated lysis. However, further studies suggested that factors other than 
CD55 should also be involved, possibly acting downstream on the complement cascade 
(Medof et al 1987; Shin et al 1986). Subsequently, CD59 (also known as Membrane Inhibitor 
of Reactive Lysis , MIRL) was identified as an additional complement inhibitor expressed on 
normal erythrocytes, while PNH erythrocytes were demonstrated deficient in CD59 
(Holguin et al 1989(a)). CD59 interferes with the terminal effector complement, blocking the 
incorporation of C9 onto the C5b-C8 complex, forming the membrane attack complex 
(MAC) (Meri et al 1990). Thus, independently from CD59 the lack of CD50 may explain 
complement-mediated hemolysis of PNH erythrocytes (Holguin et al 1989(b)). The 
hierarchical contribution of CD55 and CD59 to hemolysis suggests that CD59 is the key 
molecule which, if absent, leads to lysis (Wilcox et al 1991); in contrast, redundant 
mechanisms (including CD59 itself) usually overcome the isolated deficiency of CD55 
(Holguin et al 1992). This is also confirmed by clinical observations: in fact, patients carrying 
the so-called Inab phenotype (an isolated CD55 deficiency, with normal CD59 expression) 
do not suffer from hemolysis (Telen & Green 1989; Merry et al 1992) whereas anecdotic cases 
of CD59 deficiency lead to a clinical phenotype undistinguishable from PNH (Yamashina et 
al 1990; Motoyama et al 1992). 
4.3.3 Increased susceptibility of PNH erythrocytes to complement-mediated lysis in 
vitro and in vivo 
It is intelligible that the deficiency of the complement regulatory proteins CD55 and CD59 
renders PNH erythrocytes susceptible to uncontrolled complement activation and 
subsequent lysis. 
In vitro. The very initial studies on PNH performed by Dr. Ham associated the hemolysis 
observed in PNH patients with an intrinsic susceptibility of red cells to complement 
activation in vitro (Ham 1937; Ham & Dingle 1939). In fact, the acidified serum assay (also 
known as the Ham test) – where the acidification activates the complement through the 
alternative pathway - became the standard technique for the diagnosis of PNH. The 
abnormality resulted intrinsic to patient erythrocytes, given that hemolysis occurs 
regardless of the origin of serum, while sera from patients do not result into the lysis of 
erythrocytes from normal individuals. This assumption was also confirmed in cross-
transfusion studies (Rosse 1971). Since these initial studies it was evident that not all the 
erythrocytes drawn from a patient had the same susceptibility to complement-mediated 
lysis, making the point that all patients presented a mosaicism of normal and affected 
erythrocytes. Rosse and Dacie clearly elucidated that in erythrocytes obtained from PNH 
patients three different phenotypes could be identified, differing in their sensitivity to 
complement-mediated lysis in vitro (Rosse & Dacie 1966; Rosse 1973) . The first phenotype 
had a normal (equal to that of erythrocytes from healthy individuals) sensitivity to 
complement, while abnormal cells could have a dramatic hypersensitivity to complement-
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mediated lysis (15-25 times the normal one), or just a moderate hypersentivity (3-5 times 
normal). These phenotypes are referred as PNH type I, type III and type II, respectively 
(Rosse & Dacie 1966; Rosse 1973); now we know that they correspond to a normal 
expression of GPI-APs (type I), or to a complete (type III) or partial (type II) deficiency of 
GPI-APs, as documented by flow cytometry (van der Schoot et al 1990). Notably, PNH 
patients may have either PNH type II or type III only, or may harbor a combination of 
both phenotypes. As anticipated, the proportion of the specific phenotype shapes the 
clinical manifestations of an individual patients (especially the extent of hemolysis), and 
may vary greatly not only among patients, but even in the same patient during the course 
of the disease.  
In vivo. The in vivo consequence of the hypersensitivity of PNH erythrocyte to complement 
activation accounts for the most obvious manifestation of PNH, namely intravascular 
hemolysis and subsequent hemoglobinuria. Indeed, it is well known that PNH erythrocytes 
chronically undergo intravascular hemolysis in PNH patients in vivo, with a lifespan 
reduced to 10% compared to normal RBCs. This chronic hemolysis likely results from 
steady-state complement activation, due to the low-grade spontaneous C3 tick-over leads to 
chronic CAP activation on the PNH erythrocyte surface (Pangburn et al 1981; Pangburh & 
Müller-Eberhard 1983). It should be reiterated that both the initial complement activation 
and the down-stream effector mechanisms are uncontrolled on PNH erythrocytes. 
Specifically, the lack of CD55 impairs the regulation of C3 convertases (regardless the 
triggering pathway – classical or alternative) (Mold et al 1990), leading to increased C3 
activation and further progression along the subsequent steps of the complement cascade. 
Thus on PNH erythrocytes -- due to the lack of CD55 -- the complement cascade activated 
by the CAP continues through to MAC assembly, finally coming to lysis for the lack of 
CD59. In this view, PNH can be considered mostly a CAP-mediated disease (Holers 2008); 
in real life, this physiological low-level complement activation is greatly amplified during 
inflammatory or infectious diseases. Indeed, overt hemolysis and paroxysms of PNH 
patients likely results from a specific triggering action on the complement cascade, which 
may occur along each of the three distinct complement pathways. There are no data 
demonstrating which is the complement pathway activated in specific conditions in vivo (i.e. 
infections); however one may speculate that all the three pathways may co-operate, with a 
possible hierarchical dominance of the CAP, given its capability to amplify any complement 
activation regardless the initial triggering pathway.  
4.4 Thrombophilia and PNH 
In addition to hemolytic anemia and bone marrow failure, thrombophilia is the third typical 
manifestation of PNH; however, in contrast to the other two, much less is known about its 
pathophysiology. A number of possible mechanisms have been hypothesized, and some 
pieces of evidence have been provided, although the final mechanism remains speculative, 
possibly because it can be multifactorial. The clinical observation that thrombotic 
complications are more common in patients with larger PNH clones (Hall et al 2003; 
Grünewald et al 2003; Moyo et al 2004) and greater hemolysis may suggest that the 
pathogenic mechanism could be in some way embedded with complement activation 
(Markiewski et al 2007) and hemolysis itself. At least four distinct (but not mutually 
exclusive) mechanisms can be hypothesized. First, uncontrolled complement regulation on 
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platelet surface might lead to platelet activation and aggregation, enhancing clot formation 
(Gralnick et al 1995; Louwes et al 2001). Second, thrombophilia may directly results from 
hemolysis, due to the build-up of cell-free plasma hemoglobin released by the erythrocytes. 
This may occur through the ability of free hemoglobin to scavenge nitric oxide from plasma, 
blocking its inhibitory action on platelet aggregation and adhesion to endothelium, as well 
as its regulatory effect on vessel wall tone (Schafer et al 2004; Rother et al 2005). An other 
mechanism by which hemolysis might lead to thrombophilia includes the generation of 
procoagulant particles. In fact, microvesicles are known to be released in PNH patients upon 
hemolysis and complement activation from RBCs (Hugel et al 1999), WBCs (monocytes) and 
platelets, (Wiedmer et al 1993; Simak et al 2004) and even from the endothelium. However, 
even if their procoagulant action is commonly accepted (van Beers et al 2009), their specific 
role in the pathophysiology of thromboembolisms in PNH is not yet proven. The fourth 
possible mechanism of thrombophilia in PNH might be an impairment of the fibrinolytic 
system, due to the lack of membrane-bound urokinase-type plasminogen activator receptor 
(uPAR) -- which is GPI-linked, and to the excess of its soluble form (Ninomiya et al 1997; 
Sloand et al 2006).  
5. Clinical features 
PNH is characterized by a unique triad of clinical features: intravascular hemolysis, 
thromboembolic events and cytopenia (Dunn et al 2000; Parker & Ware 2003; Notaro & 
Luzzatto 2003). However, not all three manifestations are presents in all the patients, and the 
individual presentation of each patient may greatly vary according to the most dominant 
signs and symptoms. Thus, many investigators have tried to classify PNH according to the 
most typical clinical presentations; however, distinct categories are hard to define for a 
disease with such an unpredictable presentation and evolution.  
5.1 Classification 
The most adopted classification of PNH was proposed by the International PNH Interest 
Group in 2005 (Parker et al 2005), whereby PNH patients are grouped according to the 
presence of hemolysys and of an underlying bone marrow disorder. Accordingly, three 
distinct subtypes are identified: i. classic PNH, characterized by hemolysis without other 
marrow disorder (i.e., hemolytic PNH patients without relevant cytopenia); ii. PNH in the 
setting of another bone marrow disorder, characterized by hemolysis associated with an 
underlying marrow disorder, usually AA or MDS (i.e., hemolytic PNH patients with 
cytopenia; AA or MDS may be concomitant or have preceded PNH); iii. subclinical PNH, 
characterized by the presence of PNH cells in the absence of any clinical or laboratory sign 
of hemolysis, in the setting of other hematological disorders (i.e., AA or MDS patients with 
GPI-AP deficient cells, but not clinical PNH). This classification does not completely take 
into account that, by definition, PNH carries an underlying bone marrow disorder, and as a 
result most PNH patients have cytopenia or some signs of marrow failure. In fact, a recent 
registry study (de Latour et al 2008) made the point that many PNH patients do not fit either 
one of the two major categories, and a fourth subgroup has been included (intermediate 
PNH, characterized by hemolysis and mild cytopenia not qualifying for the diagnosis of 
AA). However, even this classification seems to fail the goal of identifying patient 
subgroups with distinct clinical outcome (de Latour et al 2008). Some other groups have 
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used in the past a different classification (Notaro & Luzzatto 2003), where the category of 
AA/PNH patients is restricted to those with concomitant severe AA and clinically 
meaningful hemolysis, who require more intensive care and are supposed to have a worse 
prognosis. According to this classification, classic PNH patients are further grouped into 
hyperplastic and hypoplastic (based on peripheral counts and bone marrow analysis), 
AA/PNH patients are only those with severe marrow failure and concomitant clinically 
relevant hemolysis, whereas subclinical PNH patients are characterized by small PNH 
clone(s) (even with minimal signs of hemolysis) associated with either AA or 
thromboembolic disease (the latter are very rare cases with a clinical PNH that does not 
include relevant hemolysis).  
5.2 Hemolysis 
Hemolysis is the most typical manifestation of PNH, which by definition affects all patients 
with clinical PNH. However, the extent of hemolysis varies among patients, according to 
size of the PNH clone(s), type of PNH erythrocytes (type II versus type III), and possibly the 
level of complement activation (which may vary according to specific medical conditions or 
patient-specific features). Typically, hemolysis is chronic (secondary to the low-level 
spontaneous complement activation), with possible exacerbations (the paroxysms) 
consequent to a massive complement activation, often in association with infections or other 
triggering events. Hemolysis of PNH erythrocytes occurs in the vessels (intravascular 
hemolysis), and leads to a number of clinical consequences. The most evident sign to the 
patient is the hemoglobinuria, with the emission of dark urine, whose aspect is commonly 
defined as “marsala wine” or coke-like, according to the Country of origin of the observer 
and/or the time of the report (Parker 2002) . The color of urine is not constant over time, 
with the most typical dark urine often seen in the morning (hence the name “paroxysmal 
nocturnal hemoglobinuria”); however, the patient’s urine mostly range from dark yellow to 
orange and dark red, with very rapid variations during the day. Even if nocturnal CO2 
retention has been hypothesized as possible cause of plasma pH fall and subsequent 
complement activation (Ham 1937), the reasons underlying nocturnal exacerbation of 
hemolysis are not yet fully understood (unless first-morning hyperconcentrated urine is not 
by itself an explanation for evident hemoglobinuria). The typical biochemical marker of 
hemolysis is the increase in lactate dehydrogenase (LDH), which may be as high as tenfold 
the upper normal value; additional intra-erythrocytary components may also increase, such 
as aminotransferases (especially the alanine one). As in other hemolytic disorders, 
unconjugated bilirubin levels may increase, even up to frank jaundice; compensatory 
erythropoiesis is usually demonstrated by very high reticulocyte counts, even if the latter 
value greatly depends upon the underlying marrow function (patients with 
hyperproliferative PNH may show even 300000-400000 cell x 109/L, while those with 
AA/PNH usually have less than 60000 cell x 109/L). Secondary iron deficiency may appear 
as a consequence of perpetual iron loss through urine. Clinically, the main consequence of 
continuous hemolysis is the development of anemia, and possibly other related symptoms 
such as asthenia and weakness. The extent of anemia is very heterogeneous among patients, 
also depending on other factors such as compensatory erythropoiesis (which may be 
impaired in patients with more severe marrow failure) or even iron/vitamin deficiency. As 
a result, anemia may be severe in some patients and requiring frequent transfusions, or  
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well-compensated in other cases, even with normal-like hemoglobin levels. Furthermore, 
anemia may greatly vary even in the clinical course of an individual patients, with sudden 
worsening or unexpected improvements in the absence of any known reason; anecdotic 
cases showing spontaneous remission of the disease have also been reported (Hillmen et al 
1995; Sociè et al 1996; de Latour et al 2008). In addition to anemia, it is now accepted that 
hemolysis may induce by itself specific disabling symptoms. This is usually seen in 
concomitance with the typical “paroxysms” of PNH, which are massive hemolytic crises often 
triggered by specific conditions (e.g., infections, surgery). These disabling symptoms include 
malaise and fatigue, with possible painful crises; the latter are quite typical, and mostly 
involve the abdomen, mimicking an acute abdomen. Some patients also report lumbar or sub-
sternal pain, headache, dysphagia (both painful and difficult swallowing) and erectile 
dysfunction (Rother et al 2005). PNH paroxysms are irregular and unpredictable in individual 
patients, although most show a quite regular recurrence in the long run period. However, 
some of these hemolysis-related symptoms (especially malaise and fatigue exceeding those 
expected based on the low hemoglobin level) can be also seen as a consequence of chronic 
hemolysis. All these symptoms, which significantly impact patient well-being , are thought to 
be due to smooth muscle dystonia secondary to local nitric oxide (NO) consumption by 
plasma free-hemoglobin (Rosse 2000, Moyo et al 2004, Rother et al 2005).  
5.3 Bone marrow failure 
The second key clinical feature of PNH is cytopenia; in contrast to erythrocytes, PNH 
granulocytes and paltelets have anormal lifespan in vivo (Brubaker et al 1977; Devine et al 
1987b); as discussed above, an underlying marrow disorder is embedded in the dual 
pathophysiology of the disease and with PNH clone expansion (Rotoli & Luzzatto 1989). 
Thus, some degree of marrow failure is common or even expected in PNH patients, ranging 
from mild cytopenias to severe aplastic anemia (Dunn et al 2000; Parker & Ware 2003; 
Notaro and Luzzatto 2003), and it may qualify for distinct disease categories (Parker et al 
2005). Remarkably, the specific picture of each individual patient may change during the 
course of the disease, with patients initially presenting with normal marrow function and 
subsequently developing more severe marrow failure, as well as patients initially diagnosed 
with aplastic anemia subsequently developing frank hemolytic PNH (Tichelli et al 1992; 
Scheinberg et al 2010). Bone marrow failure usually becomes evident because of neutropenia 
and thrombocytopenia; however, it has to be remarked that marrow failure may also 
contribute to anemia in PNH patients. In fact, many PNH patients have a reticulocyte count 
that is inadequate to the hemoglobin level (iron deficiency may also contribute to that). The 
proportion of PNH patients with marrow failure ranges from 30 to 70% in different series, 
possibly because of heterogeneous definitions of bone marrow failure itself. The most 
homogeneous data from the French registry indicate that over 430 PNH patients 26% 
presented with normal counts (neutrophils > 1.5 x 109/L, platelets > 120 x 109/L) at 
diagnosis, 52% were classified as AA/PNH (with at least two of the following: Hb < 
10gr/dL, neutrophils < 1.0 x 109/L, platelets > 80 x 109/L) and the remaining 22% as 
intermediate PNH (de Latour et al 2008).  
5.4 Thrombophilia 
The third typical manifestation of PNH is thrombophilia, with thrombosis developing in 
about 40% of all patients; accordingly, PNH is the medical condition with the higher risk of  
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thrombosis. Unfortunately, as the underlying pathogenic mechanisms are not fully 
understood, thromboses are largely unpredictable in PNH patients, even if according to 
most series they generally develop in patients with large clones and massive hemolysis 
(Hall et al 2003; Moyo et al 2004). The thrombotic risk is peculiar to each patient, possibly as 
a result of additional independent (environmental or genetic) risk factors that may shape the 
individual predisposition to thrombosis. For instance, inherited polymorphisms such as 
Factor V Leiden mutation and the 677 C>T methylenetetrahydrofolate reductase gene 
variant (as well as other polymorphisms leading to hyperhomocysteinemia) may have a 
relevant role, although this has not been proven so far (Nafa et al 1996). However, this 
concept has in someway been confirmed by the observation that the thrombotic risk is 
different in PNH patients with specific ethnicity; in fact, Asian patients have a lower 
incidence of thrombosis (Nishimura et al 2004), while Afro-Americans and Latin-Americans 
seem to have an increased incidence (Araten et al 2005). Thrombosis of PNH is quite unique, 
because it mostly occurs at venous sites which are unusual for other non-PNH-related 
thrombosis. Intra-abdominal veins are the most frequent sites, followed by cerebral and 
limb veins; other possible sites include dermal veins, the lungs – with pulmonary embolus - 
and the artheries – leading to arterial thrombosis. Thrombotic disease may be life-
threatening and is the main cause of death for PNH patients (Hillmen et al 1995; Socie et al 
1996; de Latour et al 2008). Typical severe presentations of thrombotic PNH include hepatic 
venous (Budd-Chiari syndrome) (Hoekstra et al 2009), portal, mesenteric, and renal vein 
thrombosis. Usually patients are asymptomatic, until clinical manifestations appear, 
especially pain; other signs and symptoms are specific according to the vessel involved (e.g., 
ascites, varices and splenomegaly in hepatic/portal thrombosis, or stroke in cerebral vein 
thrombosis). Unfortunately, pain is not a useful symptom by itself, because it may also be 
due to vessel wall dystonia or to a transient ischemic attack (especially of the intestine) 
rather than to true thrombosis. However, a thrombotic episode has to be suspected in all 
PNH patients with obscure pain, even when it may mimic acute abdomen; ultra sound scan 
and magnetic resonance imaging (especially angiography) are useful to rule out these 
dangerous complications. Recurrence after the first episode and/or development of chronic 
thrombotic disease is typical of PNH (Hillmen et al 1995; Socie et al 1996; de Latour et al 2008; 
Audebert et al 2005; Moyo et al 2004); this is especially common in the setting of the Budd-
Chiari syndrome, when the thrombotic process initially affects small veins, and then 
progressively involves large hepatic veins, with the development of life-threatening 
manifestations like variceal bleeding, jaundice, ascitis and liver failure. At this stage, liver 
regenerative nodules may also appear, which may erroneously suggest the presence of 
hepatocellular carcinoma. Thrombosis of other splancnic vein may usually lead to secondary 
ischemia and infarction, possibly leading to gangrene of the peripheral organ. Even if 
thromboses in PNH are unpredictable, recent data suggest that some biochemical parameters 
may work as surrogate markers of overt thrombophilia in PNH. They include D-dimers and 
other plasma markers of coagulation pathway activation, reactive fibrinolysis and endothelial 
cell activation (Helley et al 2010). However, their use has not been validated yet.  
5.5 Other clinical manifestations 
Renal failure. Both acute and chronic renal failure have been described in PNH patients (Nair 
et al 2008). Acute renal insufficiency is usually seen in concomitance with hemolytic crisis, 
as a result of massive hemoglobinuria. This condition is usually self-limiting and tends to 
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recover spontaneously in a few days after the resolution of the crisis, although specific 
interventions (even dialysis) may be needed in the acute phase. Chronic kidney disease 
(CKD) has also been reported; in a recent paper the incidence of clinically relevant CKD was 
estimated in the range of 20% (Hillmen et al 2010), but these data have not been confirmed 
by other groups (nor in previous large retrospective studies) (Hillmen et al 1995; Socie et al 
1996; de Latour et al 2008). Pathophysiologically, CKD might be related to microthrombi of 
the renal vessels, as well as to renal cortex siderosis, which can be easily demonstrated in 
PNH patients by magnetic resonance imaging.  
Infections. Infectious complications are common in PNH patients; they mostly pertain to 
cases with concomitant marrow failure, as a direct consequence of neutropenia. However, 
they could also be related to some functional impairment of PNH neuthrophils and 
monocytes, and especially of their oxidative response - which is necessary for 
microorganism destruction - as documented by some in vitro data (Cacciapuoti et al 2007).  
Pulmonary hypertension. Pulmonary hypertension (PH) has also been reported as possible 
complication of PNH by a single group (Hill et al 2006b); however, the clinical relevance of 
this observation remains to be confirmed in larger studies. 
5.6 Pregnancy  
Pregnancy is a specific issue which deserves an appropriate discussion in the setting of 
PNH. In fact, pregnancy in PNH certainly carries a high risk of complications for both 
mother and fetus. The main cause of complications is thrombophilia, which obviously 
worsen during pregnancy, and may lead to any of the thrombotic presentations described 
above. Additional risks may be related to suboptimal hemoglobin levels that hamper 
normal fetal development, as well as to cytopenia secondary to marrow failure, which may 
lead to infectious and hemorrhagic complications. It has to be remarked that, as for AA, 
pregnancy rarely causes worsening or recurrence of underlying bone marrow failure. A 
recent review (Fieni et al 2006) collecting 43 patients reported between 1965 and 2005 
estimated the range of maternal and fetal mortality to 11.6% and 7.2%, respectively, which is 
quite lower than what previously thought. All the deaths were due to thrombotic 
complications, including fetal loss secondary to placental vein thrombosis; no case of fetal 
malformation was reported. Other major maternal complications included hemorrhage and 
infections; the most common fetal complication was pre-term delivery due to maternal 
complications (including placental vein thrombosis). On the other hand, pregnancies with 
successful outcome in the absence of any complication have lso been described. Thus, 
caution should be advised in counseling PNH women about a possible pregnancy, for both 
maternal and fetal risk. Regardless of the absolute contraindication to pregnancy (which 
could be re-discussed in the era of new treatment strategies), pregnancy in PNH remains a 
high-risk medical condition which requires an experienced caring team. 
6. Natural history 
The natural history of PNH is quite unpredictable, given the very heterogeneous disease 
presentation and evolution. In fact, some patients may live with the disease for decades, 
without major complications, whereas some others present with life-threatening medical 
complications, which in any case may develop at any moment during the course of the 
disease. Thus, the evolution and outcome of an individual patient is largely unpredictable. 
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Despite the rarity of the disease, some information from large series is available, although it 
might suffer from possible selection biases (e.g., exclusion of patients with early death due 
to dramatic presentation, such as lethal thrombosis) (Hillmen et al 1995; Socie et al 1996; de 
Latour et al 2008). Median survival was estimated above 10 years in the past decade in two 
independent series, with one fourth of patients surviving longer than 25 years (Hillmen et al 
1995; Sociè et al 1996); more recently, the update of the French registry has revealed a 
median survival of about 22 years from diagnosis (de Latour et al 2008). Notably, these 
changes in median survival refer to the years before the introduction of the anti-complement 
therapy, and survival improvement was time-dependent (10-year survival was 63%, 76% 
and 92% according to diagnosis before 1995, 1995-2005 and after 2005, respectively), 
suggesting a relevant improvement in supportive care. Survival does not differ according to 
disease category: in fact, 10-year overall survival was 75%, 82% and 74% in classic PNH, 
intermediate PNH and AA/PNH, respectively. The main causes of death were thrombosis 
(cerebral thrombosis 25%, Budd-Chiari 23% - expressed as percentage of all deaths) and 
infectious complications (25%); they were both major causes of morbidity too. Even if PNH 
is not a malignant disease, progression to myelodysplastic syndrome and acute leukemia 
was observed with a 10-year cumulative incidence of 3.8%, which is similar to previous 
series (Hillmen et al 1995; Sociè et al 1996; Fujioka & Asai 1989) and to that reported for AA 
patients. Thrombosis developed in about 50% of classic PNH and 30% of intermediate PNH 
or AA/PNH patients; marrow failure developed in about 25% of classic and intermediate 
PNH patients. In the whole series, thrombosis was the main negative prognostic factor, 
followed by development of by- or pan-cytopenia, lower hemoglobin levels and previous 
diagnosis. Thrombosis affected long-term survival in all disease categories, including 
AA/PNH; risk factors for the development of thrombosis included thrombosis at diagnosis, 
old age, transfusion and lack of immunosuppressive treatment, and PNH clone size. 
Recurrent infections affected up to 40% of patients, representing the second main clinical 
complications of PNH; hemorrhage was an other relevant complication, especially in 
thrombocytopenic patients. Thus, even if most PNH patients may have a quite long life 
expectancy, the course of their disease may be stormy, with frequent hospitalizations, 
possible comorbidities and subsequent impaired quality of life. On the other hand, some 
patients may experience an indolent course, without major complications; a few PNH 
patients may also undergo spontaneous clinical remission of their disease, which can be 
estimated in about 5% (de Latour et al 2008) (even if an older study reported up to 15%, 
possibly due to definition bias) (Hillmen et al 1995). It has to be underlined that these data 
on the natural history of the disease might significantly change in the current era of effective 
anti-PNH treatment, mainly eculizumab or even bone marrow transplantation.  
7. Diagnosis 
PNH has to be suspected in patients showing mild to severe anemia with moderate 
reticulocytosis, elevated serum LDH and possibly mild jaundice, with negative Coombs test; 
all these clues suggest a non-immune hemolytic anemia. The occurrence of dark urine and 
urinary hemosiderin, both evidence of intravascular hemolysis, strongly support the suspect 
of PNH; haptoglobin is usually very low or undetectable. Additional signs to be considered 
are the presence of mild to severe leuko-thrombocytopenia and/or a history of 
thromboembolic events of unknown origin, including cerebrovascular accidents. In specific 
conditions, PNH may be considered even in the absence of clinically evident hemolytic 
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anemia, such as in patients with AA or those showing recurrent thromboembolic events in 
the absence of documented risk factors; all these patients may deserve a careful screening 
for PNH. Diagnostic tests for PNH have much changed in the past three decades: the Ham 
test, which was the diagnostic test until the 1980s, has been completely replaced by flow 
cytometry. 
The Ham test 
Historically, the Ham test, also known as acidified serum assay, was since its identification 
in the 1930s the best test to diagnose PNH. Indeed, even the pathophysiological definition of 
PNH is based on the increased susceptibility of affected erythrocytes to complement 
mediated lysis (Rosse & Dacie 1966; Rosse 1991). The Ham test is an in vitro assay which 
employs this unique feature of PNH erythrocytes, testing the lysis in sera where the 
complement cascade (and specifically the complement alternative pathway) has been 
activated by pH lowering (by the addition of HCl). In these conditions, erythrocytes from 
PNH patients show a substantial lysis, which may vary according to the proportion of 
affected (PIG-A mutated) cells and to the type of mutation (type II versus type II PNH). 
Hemolysis occurs in both autologous and ABO-matched sera; as a control, lysis does not 
occur if the serum has been inactivated at 56° C (which inactivates some complement 
components), or when erythrocytes from healthy individuals are tested. In experienced 
hands, the test is relatively simple, and quite specific; however, its sensitivity is limited, with 
a threshold of about 5-10% PNH erythrocytes required for a definitive diagnosis. Other lysis 
assays exist, such as the sucrose lysis (or sugar water test); they exploit reduced ionic 
strength rather than acidification-based complement activation. However, their sensitivity 
and specificity for PNH are worse than those of the Ham test, and false positive may be 
common in other inherited hemolytic conditions. Obviously, all these lysis assays may only 
detect the presence of PNH erythrocytes, but cannot be utilized to detect cells with a PNH 
phenotype within any other blood lineage. 
Flow cytometry 
At present the diagnosis of PNH is based on flow cytometry analysis of blood cells (Parker 
et al 2005; Richards et al 2002); the high sensitivity and specificity of this analysis has made 
the Ham and similar tests obsolete. In fact, fluorochrome-conjugated monoclonal antibodies 
specific to several GPI-APs expressed on the various blood cell lineages are available for 
routine testing; thus, simultaneous multi-parameter analysis allows accurate detection of 
GPI-AP deficient cell populations, measuring their extent within each blood lineage 
(erythrocytes, granulocytes, monocytes and lymphocytes). By this technique, one or two 
erythrocyte populations with abnormal expression of GPI-APs may be found in PNH 
patients: one completely lacking GPI-AP expression (type III PNH cells), and another 
characterized by GPI-AP faint (dim) expression (type II PNH cells). These findings match 
the observation initially made by Dr. Rosse, demonstrating the presence of distinct 
subpopulations of erythrocytes with different sensitivity to complement-mediated lysis 
(Rosse & Dacie 1966); as discussed above, this may also imply that different populations 
may be genetically different. The demonstration of GPI-AP deficient populations is easy for 
all cell lineage, even if discrimination between type II and type III PNH cells is more 
difficult for white blood cells; antibodies specific for GPI-APs selectively expressed by 
specific cell lineage may render the test more sensitive and specific. Different panels of 
monoclonal antibodies have been proposed by different groups (Richards et al 2000; 
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Borowitz et al 2010); they usually include CD55 and CD59 for erythrocytes, CD66b, CD66c 
and CD24 for granulocytes, CD14 or CD48 for monocytes, CD48 or CD59 for lymphocytes. 
A counter-staining for gating strategies on specific blood cell populations may be included; 
in fact, a complete testing for PNH includes the analysis of erythrocytes, granulocytes, 
monocytes, and possibly lymphocytes (even if they are usually minimally affected, because 
most of them are long-living cells sustained by peripheral homeostasis). Platelets are usually 
not tested for PNH phenotype, due to the difficulty to separate normal platelets from PNHs 
(Maciejewski et al 1996; Vu et al 1996). The simultaneous absence of different GPI-linked 
proteins on the same cells validates the specificity of the test; as far as the sensitivity is 
concerned, flow cytometry analysis in experienced hands may detect even very small PNH 
clones (below 1% in routine testing, (Borowitz et al 2010) up to 0.01% in ultra-sensitive 
analysis for research purpose) (Araten et al 1999; Sugimori et al 2006). More recently, the 
novel fluorescent reagent aerolysin (FLAER), which specifically binds to the GPI anchor, 
showed even greater sensitivity for the detection of small PNH cell population, up to 0.01% 
as a single marker (Brodsky et al 2000; Sutherland et al 2007). FLAER can be easily combined 
with other monoclonal antibodies for a comprehensive and simultaneous study of all blood 
leukocytes. However, given that FLAER requires to be processed by proteolytic enzymes 
expressed on leucocyte surface, it cannot be utilized detect PNH erythrocytes or platelets. 
Molecular studies 
Molecular studies on DNA or mRNA, aimed to identify the specific causative mutation 
within the PIG-A gene, are usually considered superfluous rather than confirmatory. In fact, 
they do not add any clinically informative data and can even be somewhat misleading. 
Indeed, a false negative result may occur, especially when mononuclear cells are used as 
nucleid acid source (proportion of PNH lymphocytes are minimal in the majority of 
patients), or in case of some intronic mutations; on the other hand, false positive results may 
also occur due to the intrinsic sensitivity of the technique. Notably, molecular studies do not 
deliver the most relevant information as flow cytometry-based assay, which is the exact 
proportion of affected GPI-deficient (thus PIG-A mutated) cells. Thus, molecular testing is 
not recommended for the diagnosis of PNH. 
Blood 
The blood film is usually not very informative in PNH patients. Red blood cells are usually 
macrocytic due to reticulocytosis (which can be demonstrated by vital dyes), but cell size 
may greatly vary. Polychromatophilic or even nucleated erythrocytes may be present as a 
result of compensatory erythropoiesis. Microcytic hypocromic erythrocytes may also be 
present, because of the secondary iron deficiency; red cell fragments may be observed, 
especially in concomitance with thrombotic complications. Leukocytes do not show any 
abnormality, even if neutropenia is commonly seen in patients with AA/PNH; 
thrombocytopenia is also quite frequent.  
Coombs test 
The differential diagnosis of PNH includes all other hemolytic conditions; thus, the Coombs 
test should be performed as initial assay. By definition, the Coombs test is negative in PNH, 
as it is a non-immune hemolytic anemia. However, it has to be remarked that a positive 
Coombs test may result from allo-immunization secondary to transfusion. More recently, it 
has been shown that a C3-only positive Coombs test may develop in most PNH patients on 
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eculizumab treatment (Risitano et al 2009a); this finding is not due to any antibody, but 
rather it derives from mechanistic reasons that will be discussed later on.  
Bone marrow 
The bone marrow pattern may be significantly different according to the presentation of the 
disease. In fact, patients with classic PNH may present with hyperproliferative bone 
marrow, and markedly increased erythropoiesis; however, due to the underlying bone 
marrow disorder, they may also present normal or even reduced marrow cellularity. The 
latter pattern is typical in AA/PNH patients, where cellularity is below 30%, as assessed by 
threphine biopsy. Commonly, morphological abnormalities may be observed, sometimes 
leading to the misdiagnosis of MDS; it has to be underlined that in most cases such 
abnormalities are not specific and simply reflect the stressed erythropoiesis. Additional tests 
can be performed on bone marrow specimens. Cytogenetic studies may occasionally reveal 
karyotypic abnormalities, which may occur in either PNH or normal cells; however, they do 
not necessarily carry a bad prognosis as for MDS (Araten et al 2001). Flow cytometry may be 
used to rule out leukemic transformation; given that surface expression of most GPI-APs 
undergoes changes during differentiation and maturation, bone marrow flow cytometry is 
not recommended for the diagnosis of PNH. 
Urine 
Even a macroscopic observation of urine may be a useful tool for the diagnosis of PNH; in 
fact, eye-evident hemoglobinuria may be one of the clinical presentations. Plasma free 
hemoglobin secondary to intravascular hemolysis depletes haptoglobin; as a result, free 
hemoglobin is continuously present in the glomerular filtrate. The excess hemoglobin is 
partially reabsorbed in the proximal tubule, and the iron stored as intracellular ferritin 
granules easily detected in the urine cast by appropriate iron (Perl’s) staining – as 
hemosiderin granules. Hemosiderinuria is constantly present in all hemolytic PNH patients 
(even in the absence of hemoglobinuria, which fluctuates according to the concomitant 
hemolysis), thus it still represents an easy test to support the initial suspect of PNH.  
Other instrumental studies 
The management of PNH patients may require many other laboratory and instrumental 
studies useful to investigate the evolution of the disease and its possible complications. They 
especially include all the techniques useful to assess the presence of possible thrombosis; 
according to the specific sites, the most useful are computed tomography or magnetic 
resonance based, (for the cerebral and sometimes the hepatic districts), or ultra-sound based 
(for the abdomen and limbs). Specific angiographic studies are always helpful, especially 
once a thrombotic episode has been demonstrated (and always for the assessment of the 
cerebral district), to better assess the extent of the clot and its evolution. All these studies 
should be performed without delay, at diagnosis and/or in the presence of specific 
symptoms. 
8. Treatment 
The treatment of PNH is driven by the specific disease presentations (Brodsky 2009; 
Luzzatto et al 2011); however, in most cases treatment is essentially supportive, aiming at 
living with the disease with the least clinical burden. Thus, the main goals of PNH treatment 
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includes the control of anemia and possibly of hemolysis; in patients with either marrow 
failure or thrombosis additional specific treatments are needed. Given the chronic course of 
PNH, an other major goal is the prevention of possible complications, mainly thrombosis 
and infections, to ensure long-term survival. More recently, etiological treatments for PNH 
have become available with the introduction of the first anti-complement agent, the anti-
complement component 5 (C5) eculizumab. Finally, the only curative option for PNH is 
allogeneic stem cell transplantation.  
8.1 Supportive therapies 
The supportive treatment of PNH aims to control the main clinical manifestations of the 
disease; thus, it can be split according to specific manifestation – hemolysis and subsequent 
anemia, bone marrow failure and thrombocytopenia. 
8.1.1 Management of hemolysis and anemia 
Hemolysis and subsequent anemia are the hallmarks of PNH, affect most PNH patients and 
often require specific treatment. Unfortunately, until the new millennium there was no 
specific option for controlling hemolysis. Steroids were broadly used as chronic 
administration or for acute hemolytic crises, without any proof of efficacy. Indeed, some 
investigators claimed that steroids are useful in controlling chronic complement-mediated 
hemolysis (Issaragrisil et al 1987; Bourantas 1994) and, even more, paroxysmal crises likely 
interfering with complement activation and/or the underlying conditions (i.e., 
inflammation) triggering the complement cascade; however, so far no mechanism of action 
has been provided. It has been suggested that steroids might ameliorate patient well-being 
even in the absence of any direct control of hemolysis (Parker et al 2005); in particular, they 
may be effective in improving the symptoms associated with paroxysmal crises, such as 
dysphagia and abdominal pain, although this effect in most cases may result from the self-
limiting behavior of the paroxysms. However, a continuous use of steroids is discouraged in 
PNH patients, given the long-term toxicity of chronic steroidal therapy; a short-term use in 
presence of the paroxysms is not harmful but likely useless. Androgens have been utilized 
as well, with limited benefit (Harrington et al 1997); however, given their potential utility in 
stimulating erythropoiesis and especially megakaryocytopoiesis (Katayama et al 2001), they 
are primarily indicated in the presence of marrow impairment rather than to control 
hemolysis (see below). Once again, a risk-to-benefit evaluation should be specifically made 
for all individual cases, given that liver toxicity, virilizing action and other side effects have 
to be considered; in addition, some concerns about a potential increase in the Budd-Chiari 
syndrome have been raised by some physicians (Parker et al 2005). Regardless of the 
possibility to block hemolysis, in many patients anemia leads to clinically relevant 
symptoms requiring specific interventions. As remarked in the pathophysiology section, 
anemia of PNH patients is someway multi-factorial; thus, if the main contributor 
(hemolysis) cannot be affected, one may try to interfere with the additional mechanisms to 
improve hemoglobin levels. Besides hemolysis, the main factor affecting hemoglobin level is 
the bone marrow function, especially its capability to adequately compensate the ongoing 
hemolysis. By definition, erythropoiesis is usually impaired in patients with AA/PNH 
syndrome, who may require specific treatments (see below); however, ineffective 
erythropoiesis is commonly seen even in classic PNH patients. Given the perpetual 
hemosiderinuria, iron deficiency is common in PNH patients (Luzzatto et al 2011), and 
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simple iron supplementation may increase hemoglobin levels in many patients. Similarly, 
vitamin B12 and folate supplementation are usually indicated to sustain the compensatory 
erythropoiesis secondary to hemolysis (Luzzatto et al 2011). Erythroid stimulating agents, 
essentially recombinant erythropoietin, may also help enhance erythropoiesis (Stebler et al 
1990; Bourantas et 1994), especially in cases showing inadequate production of endogenous 
erythropoietin (McMullin et al 1996). Paradoxically, all these strategies may be of limited 
clinical benefit, because of the increased hemolysis (and hemolysis-related symptoms) 
resulting from the production of PNH erythrocytes susceptible to complement-mediated 
lysis. Notwithstanding these interventions, moderate to severe anemia may develop in a 
substantial proportion of PNH patients, for whom transfusions are the main strategy to 
control anemia. RBC transfusions are given to PNH patients according to their hemoglobin 
level; as for other chronic anemic patients, transfusions should be administered to maintain 
hemoglobin levels above 8 gr/dL. Transfusions transiently improve anemia-related 
symptoms, as well as hemolysis-related symptoms (the production of PNH erythrocytes 
temporarily decreases by effect of the higher hemoglobin levels). Remarkably, in contrast to 
other transfusion-dependent patients, iron overload is usually not a transfusion-related 
complication in PNH, given the massive iron loss through urine; this may change in PNH 
patients receiving transfusions during eculizumab treatment (Risitano et al, 2009b). 
However, as in other transfusion-dependent patients, refractoriness to transfusion may 
develop, mostly due to allo-sensitization. Refractoriness to transfusions was considered a 
severe complication requiring alternative treatment − even stem cell transplantation; 
however, nowadays it is not necessarily a severe complication, given the availability of the 
anti-complement treatment by eculizumab. Eculizumab has also dramatically changed the 
management of hemolysis for all PNH patients with meaningful hemolysis, as discussed 
later on. 
8.1.2 Management of marrow failure 
The management of marrow failure in PNH patients is the same as for AA patients, and 
represents the main challenge for physicians dealing with the treatment of this condition 
(Risitano 2011). Indeed, in addition to supportive strategies such as anti-infectious, anti-
thrombotic and anti-hemorrhagic prophylaxis and/or treatment, etiologic therapies can also 
be attempted. According to the pathogenic mechanisms and the dual hypothesis described 
above, an immune-mediated inhibition of hematopoiesis is postulated in PNH, similar to 
that demonstrated in AA. Thus, immunosuppressive strategies have been reasonably 
utilized in PNH patients, even if large prospective studies are lacking. Cyclosporine A has 
led some improvement in a few series (Schubert et al 1997; Stoppa et al 1996; van Kamp et al 
1995). More intensive regimens (as those recommended in severe AA) using the anti-
thymocyte globulin associated with high dose prednisone and cyclosporin A have also been 
exploited; however, the available results are quite heterogeneous (Tichelli et al 1992; 
Sanchez-Valle et al 1993). Alternative immunosuppressive agents such as 
cyclophosphamide (Brodsky et al 2010) or the anti-CD52 monoclonal antibody 
alemtuzumab (Risitano et al 2010a) may be an alternative option (as salvage treatment); in 
the setting of alemtuzumab-based treatment, there is no concern over the potential selection 
risk for PNH hematopoiesis, given that the GPI-linked CD52 is not expressed on HSCs. 
Regardless of the specific immunosuppressive regimen, when this etiological treatment 
leads to an improvement of the underlying bone marrow impairment, usually normal (non-
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PNH) hematopoiesis may be restored, possibly resulting in a progressive dilution (or even 
extinction) of the PNH clone. However, some patients may continue to have remarkable 
hemolysis due to the persistence of the PNH clone(s). In addition to the immunosuppressive 
therapy, it has to be pointed out that marrow failure represents the main indication to 
allogeneic stem cell transplantation for PNH patients; in fact, all young PNH patients with 
bone marrow failure should be considered for transplantation if they have a HLA-matched 
donor (Luzzatto et al 2011), or even if they have an unrelated donor (later in their disease 
course). Indeed, marrow failure of PNH patients has to be treated as aplastic anemia by 
either immunosuppression or allogeneic stem cell transplantation, regardless of the 
presence of the PNH clone(s) (Risitano 2011).  
8.1.3 Management of thrombophilia 
The management of the propensity to develop thrombosis is the hottest issue in PNH, since 
this complication represents the first cause of death. Unfortunately, there are no controlled 
prospective clinical trials concerning either primary and secondary thrombosis prophylaxis, 
or acute treatment of the event. The issue of primary prophylaxis is controversial, and no 
consensus exists; some physicians advocate the use of warfarin for all newly diagnosed 
PNH patients, while others do not use any prophylaxis. Both approaches are reasonable, 
given the unpredictability of thromboembolic events and the lack of evidence supporting 
any of these strategies; possible benefits are counterbalanced by the risk of hemorrhage from 
warfarin therapy, which may be considerable in PNH patients with low platelet count. 
Given that up to two thirds of PNH patients may never develop any thrombosis during the 
course of their disease, some physicians consider unacceptable to risk hemorrhagic 
complications (especially in those who are thrombocytopenic); this perception is 
strengthened by the fact that current primary prophylaxis is not necessarily protective in all 
patients (de Latour et al 2008; Luzzatto et al 2011). A reasonable compromise may be the 
adoption of primary prophylaxis for patients at higher risk of thrombosis, which can be 
identified by the presence of additional inherited (e.g., ethnicity, factor V Leiden) or 
acquired (e.g., lupus anti-coagulant, pregnancy) risk factors for thrombosis. A single group 
reported that prophylaxis by warfarin in patients with WBC PNH clones larger than 50% 
resulted in a very low incidence of thromboembolic events compared to historical controls 
(Hall et al 2003); however, hemorrhagic complications (even fatal) were also observed, and 
these date need to be confirmed in larger, possibly prospective studies. To data, there is no 
experience with newer and possibly more manageable agents, such as thrombin inhibitors, 
which might play a major role in the future. In contrast, as far as secondary prophylaxis is 
concerned, there is general agreement that all PNH patients experiencing any 
thromboembolic event should remain life-long on anticoagulants; however, even in this 
setting, no consensus exists about the best strategy. Low-molecular-weight heparin, as well 
as warfarin at different therapeutic ranges, are both utilized, with some physicians even 
considering the addition of anti-platelet agents; most physicians start with heparin, and 
subsequently shift to warfarin. However, despite the extended prophylaxis, recurrence of 
thrombosis (either as new events or progression of the existing ones) is frequent and affects 
the survival of PNH patients (Audebert et al 2005; de Latour et al 2008). Moreover, life-
threatening hemorrhagic events are quite frequent in this cohort of patients, mostly when 
concomitant thrombocytopenia is present (Hall et al 2003, Moyo et al 2004). Finally, the 
management of an acute thromboembolic disease may require an intensive therapy similar  
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to that for myocardial infarct; in addition to anti-coagulants at therapeutical doses, 
fibrinolytic therapies using tissue plasminogen activator have been exploited, showing 
efficient clearance of the thrombus in individual cases (McCullin et al 1994; Hauser et al 
2003; Sholar & Bell 1985; Araten et al 2010). As for hemolytic anemia, the management of 
thrombophilia has substantially changed with the introduction of eculizumab. 
8.2 Anti-complement treatment 
8.2.1 Eculizumab: A humanized anti-complement component 5 monoclonal antibody 
Eculizumab (h5G1.1-mAb, Soliris®, Alexion Pharmaceuticals) is a humanized monoclonal 
antibody (mAb) (Rother et al 2007) derived from the murine anti-human C5 mAb; it 
specifically binds the terminal complement component 5, thereby inhibiting its cleavage to 
C5a and C5b (Matis & Rollins 1995). Thus, eculizumab blocks the formation of MAC, the 
terminal effector mechanism leading to intravascular hemolysis of PNH erythcocytes. The 
blockade of the complement cascade at the level of C5 does not affect early complement 
components, preserving pivotal functions such as clearance of immune complexes and 
microorganisms (Matis and Rollins 1995). Eculizumab was initially investigated in patients 
suffering from other complement-mediated disorders; however, PNH appeared the best 
candidate disease to benefit from eculizumab treatment. In fact, eculizumab may 
compensate for the absence of CD59 on PNH erythrocytes, preventing their lysis upon 
complement activation (which is also uncontrolled given the absence of CD55). Eculizumab 
is administered intravenously, thus its bioavailability is 100%; its estimated half-life is 271 
hours. Eculizumab therapy was designed to rapidly reach pharmacodynamic levels using 
an induction regimen, followed by a maintenance dosage schedule aiming to avoid 
concentration drops below the plasma level of 35 μg/mL (Hillmen et al 2006), which is the 
threshold level for pharmacodymanic effectiveness (based on in vitro data). In all PNH 
studies eculizumab has been administered intravenously as 4 weekly doses of 600 mg 
(induction regimen), followed by 900 mg doses every other week (maintenance regimen), 
starting 1 week after induction (week 5); this is the standard schedule, approved by the FDA 
for the treatment of hemolysis in PNH patients. 
8.2.2 Safety and efficacy of eculizumab 
Eculizumab and intravascular hemolysis: efficacy from the registration studies. The management of 
hemolysis of PNH, which was palliative until 2000, has dramatically changed with the 
availability of eculizumab (Brodsky 2009; Luzzatto et al 2011). In the last few years 
eculizumab has been extensively investigated for the treatment of hemolysis in patients with 
transfusion-dependent PNH. Safety and efficacy of eculizumab were initially established in 
a phase II pilot study (Hillmen et al 2004) as well as in two phase III clinical studies 
(TRIUMPH and SHEPHERD) (Hillmen et al 2006; Brodsky et al 2008), and subsequently 
were confirmed in a common open-label Extension study (Hillmen et al 2007). All patients 
receiving eculizumab were vaccinated against Neisseria Meningiditis at least two weeks 
before starting treatment. After the initial pilot study, which provided the proof-of-principle 
of effective blockade of intravascular hemolysis in eleven heavily transfused PNH patients 
(Hillmen et al 2004), eculizumab was tested in a double-blind, placebo-controlled, 
multinational randomized trial which enrolled 86 patients (Hillmen et al 2006). The 
eligibility criteria included at least 4 red cell transfusions in the previous 12 months, a PNH 
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type III erythrocyte population ≥10%, platelets ≥100 x 109/L, and lactate dehydrogenase 
(LDH) ≥1.5 times the upper limit of normal (Hillmen et al 2006). Treatment with eculizumab 
resulted in a dramatic reduction of intravascular hemolysis, as measured by LDH, leading to 
hemoglobin stabilization and transfusion independence in about half the patients. Control of 
intravascular hemolysis was achieved in all patients, and even cases who still required 
transfusions showed a reduction of their transfusional needs. The effects of eculizumab on 
hemolysis were evident after the first administration, and lasted for the whole study period. 
Compared to placebo, eculizumab significantly improved fatigue and quality of life, as 
measured by validated questionnaires (Hillmen et al 2006). These data were confirmed in 
the open-label phase III study SHEPHERD, which included a broader PNH population 
(minimum pretreatment transfusion requirement was one, and minimum platelet count 
requirement was 30 x 109/L) (Brodsky et al 2008). In the 96 patients enrolled in the study, 
treatment with eculizumab resulted in an almost complete control of intravascular 
hemolysis, regardless of the pretreatment transfusion requirement, with transfusion 
independence achieved in half the patients, and significant improvement in fatigue and 
quality of life (Brodsky et al 2008). The subsequent open-label Extension study enrolled a 
total of 187 patients who had previously completed one of the parent clinical trials (Hillmen 
et al 2007). The Extension study confirmed the efficacy and safety of eculizumab with a 
longer follow up, confirming that the effects of eculizumab treatment on intravascular 
hemolysis were retained over time (Hillmen et al 2007). 
Eculizumab and thrombophilia. The Extension study included as a secondary endpoint the 
assessment of thrombotic risk in PNH patients chronically receiving eculizumab treatment, 
by looking to the incidence of thromboembolic events in the pretreatment and treatment 
periods in the same patients (Hillmen et al 2007). The rate of thromboembolism decreased 
from 7.37 to 1.07 events/100 patient-years after eculizumab treatment, with a 85% relative 
reduction. This reduction was preserved even in patients on anticoagulants, suggesting that 
eculizumab may be the most effective agent to prevent thromboembolisms in PNH patients 
(Hillmen et al 2007). Whether eculizumab exerts its effect on thrombophilia of PNH directly, 
or through the blockade of intravascular hemolysis (e.g., by reduction of NO consumption 
or reduced release of procoagulant microvesicles), it is still unknown. Recently, it has been 
reported that eculizumab treatment results in a significant decrease in the plasma markers 
of coagulation pathway activation, reactive fibrinolysis and endothelial cell activation 
(Helley et al 2010). This finding suggests that the pathophysiology of thrombosis in PNH 
may involve multiple pathways, and that the triggering events possibly affected by 
eculizumab have not been yet identified. However, if the protective effect of eculizumab on 
the thromboembolic risk are confirmed in a long-term period, it is reasonable to anticipate 
that eculizumab may result in an improvement of survival of PNH patients. Such effect on 
survival has been recently shown in a limited cohort of patients (Kelly et al 2011).  
Eculizumab and PNH: any additional benefit? More recently, it has been reported that 
eculizumab may lead to additional beneficial effects for PNH patients. As stated before, by 
inhibiting intravascular hemolysis eculizumab controls all hemolysis-related symptoms, 
including painful crisis, dysphagia and erectile dysfunction (Hill et al 2005). In addition, by 
counteracting NO consumption, eculizumab might reduce the risk of pulmonary 
hypertension (PH) (Hill et al 2010b). This conclusion was mainly derived from the 50% 
reduction of N-terminal pro-brain natriuretic peptide (NT-proBNP), which was elevated at 
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baseline in about 50% of PNH patients. Unfortunately this study does not include a direct 
estimation of pulmonary artery pressure by doppler echocardiography, making it uncertain 
as to whether these PNH patients exhibited clinically relevant PH. However, even if NT-
proBNP can be considered a non-invasive marker for PH, possibly reflecting increased 
pulmonary vascular resistance and right ventricular dysfunction, it is usually utilized as 
prognostic marker in patients with proven diagnosis of PH. In another study, eculizumab 
appeared to improve renal function of PNH patients, as measured by estimated glomerular 
filtration rate (eGFR), preventing possible CKD (Hillmen et al 2010). The authors report that 
before treatment a fraction of PNH patients may have decreased eGFR, qualifying for stage 
3-5 CKD (about 20%); eculizumab treatment resulted in an improvement of eGFR, and 
reduced the risk of major clinical kidney events. Nevertheless, PH and CKD are not 
commonly described in PNH patients (de Latour et al 2008); therefore, the real clinical 
impact of these finding has to be assessed in appropriate studies. 
Eculizumab and pregnancy. Most hematologists try to dissuade PNH women from pursuing 
pregnancy, due to both maternal and fetal risk of complications, mainly secondary to 
thrombosis. Since eculizumab has became available, three pregnancies have been reported 
in women on this agent all through the gestation period; all of them had healthy newborns, 
without any maternal complication (Kelly et al 2010; Marasca et al 2010). Thus, even if 
eculizumab is formally not indicated in PNH pregnant women, and indeed the label for 
eculizumab classifies it as a pregnancy class C drug, common sense suggests that 
eculizumab be not automatically withdrawn in the case of pregnancy, giving careful 
consideration to the need to control the major causes of both maternal and fetal morbidity 
(intravascular hemolysis and subsequent anemia, and thrombophilia). It is still a matter of 
debate whether these data are sufficient to change our current counseling, allowing highly 
motivated PNH women to start pregnancy during eculizumab treatment. 
Safety and tolerability of eculizumab treatment. The safety profile of eculizumab was assessed in 
the six studies involving PNH patients (Hillmen et al 2006; Brodsky et al 2008; Hillmen et al 
2007), as well as on eleven studies utilizing eculizumab for different indications; the 
cumulative exposure was 147.44 and 492.20 patient-years in the two populations, 
respectively. Three deaths were reported in the PNH studies, all related to the underlying 
disease in two cases (one cerebral vascular accident and one progression to chronic 
myelomonocytic leukemia) and to an unrelated accident in the third (cerebral herniation). 
The main concern was a putative increased risk of infections, mostly by encapsulated 
bacteria, namely Neisseria Spp. Given the occurrence of a single case of meningitis by 
Neisseria meningitidis in the initial non-PNH cohort, all patients exposed to eculizumab were 
vaccinated against Neisseria meningitidis using a polyvalent vaccine. In addition, all patients 
received a warning on meningitis and infectious symptoms, as well as a rescue antibiotic 
prescription. No case of meningitis has been documented among the 195 PNH patients 
receiving eculizumab in the clinical trials; however, three patients developed a Neisseria 
meningitidis infection (possibly from N. meningitidis groups not covered by the prescribed 
vaccine), with sepsis in two cases. None of these patients developed meningitis or other 
complications, and all recovered promptly as a result of early diagnosis and treatment. The 
incidence of serious adverse events was similar in eculizumab-treated patients and in those 
receiving the placebo within the TRIUMPH trial; furthermore, none of the serious adverse 
events was considered as possibly, probably or definitely related to eculizumab. The overall 
rate of infectious events did not increase compared to the placebo group; however, herpes 
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simplex and some other site-specific infections (nasopharyngitis, upper respiratory tract 
infection, urinary tract infection and sinusitis) appeared to be more frequent within the 
eculizumab-treated population. However, in all cases the intensity was mild and the clinical 
resolution prompt. The occurrence of immunogenity was assessed, and was demonstrated 
to be very infrequent, if at all present, and without consequence on drug efficacy. In 
summary, the treatment with eculizumab is safe and well-tolerated for the treatment of 
PNH, with negligible side effects (Hillmen et al 2006). Long-term treatment has not shown 
any deviation from this safety profile, as confirmed by post-marketing experience; however, 
anti-meningococcal vaccination and warning for symptoms of meningitis remains 
mandatory.  
8.2.3 Emerging observations during treatment with eculizumab 
C3-mediated extravascular hemolysis during eculizumab treatment. Since the introduction of 
eculizumab in 2005, growing evidence suggests that its effect on MAC inhibition may 
unmask a biologically relevant and potentially pathogenic role for the early phases of the 
complement cascade. We have recently documented that a novel, clinically significant 
finding may appear in PNH patients receiving eculizumab, accounting for some portion of 
residual anemia and heterogeneous hematological benefit from treatment (Risitano et al 
2009a). In fact, while basically all patients achieve normal or almost normal LDH levels 
(pointing out an adequate control of intravascular hemolysis), only about a third reach a 
hemoglobin value above 11 gr/dL). In contrast, the remaining patients on eculizumab 
continue to exhibit moderate to severe (transfusion-dependent) anemia, in about equal 
proportions. In our initial series of 56 PNH patients, we have demonstrated by flow 
cytometry that all the 41 PNH patients on eculizumab harbored C3 fragments bound to a 
substantial portion of their PNH erythrocytes (while none of the untreated patients did) 
(Risitano et al 2009a). Our data were confirmed in an independent series by an other group 
that exploited a direct antiglobulin test using C3d-specific anti-sera (Hill et al 2010a). We 
concluded that membrane-bound C3 fragments work as opsonins on PNH erythrocytes, 
resulting in their entrapment by reticuloendothelial cells through specific C3 receptors and 
subsequent extravascular hemolysis (Risitano et al 2009a; Luzzatto et al 2010). This 
mechanism is supported by persistent reticulocytosis, hyperbilirubinemia and anemia in 
patients on eculizumab, and was also confirmed by an in vivo erythrocyte survival study by 
51Cr labeling (which showed reduced survival and hepatosplenic 51Cr uptake) (Risitano et al 
2009a).  
The complement cascade regulation during eculizumab treatment. Pathophysiologically, it is clear 
that such a mechanism becomes evident only when eculizumab prevents MAC-mediated 
hemolysis, allowing longer survival of PNH erythrocytes, which continue to suffer from 
uncontrolled C3 convertase activation and C3 fragment deposition due to CD55 deficiency 
(Luzzatto et al 2010; Risitano et al 2011). Indeed, CAP is physiologically in a state of 
continuous activation because spontaneous (low-grade) hydrolysis of an internal thioester 
bond of C3 generates a C3b-like molecule, C3(H2O); nascent C3(H2O) is able to recruit factor 
B in forming (in the fluid phase) an unstable pro-C3 convertase. Once cleaved by factor D 
(generating C3(H2O)Bb), this complex will in turn cleave additional C3 molecules to 
generate C3b, which binds predominantly to glycophorin A and activate (now in a 
membrane-bound phase) the CAP amplification loop (Parker et al 1982; Pangburn et al 
1983c; Müller-Eberhard 1988; Risitano et al 2011). On PNH erythrocytes, the lack of CD55 
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will allow this process (which is self-limiting on normal cells) to continue, leading to 
progressive CAP-mediated amplification, even in the presence of eculizumab (which acts 
downstream). The reasons why only a fraction of PNH erythrocytes has membrane-bound 
C3, and why the proportion varies among patients, are not fully understood. Nevertheless, 
in vitro data support the concept that PNH erythrocytes are all susceptible to C3 deposition 
once exposed to conditions causing complement activation (Sica et al 2010). We have 
hypothesized that inter-individual differences in other physiological inhibitors (such as CR1 
, complement FH and complement FI) may modulate the complement activation in a 
patient-specific fashion, leading to distinct patterns of C3 deposition. In addition, even more 
complex factors may drive the subsequent fate of C3-bound PNH erythrocytes; in fact, some 
patients may harbor large proportion of C3-bound PNH erythrocytes, without showing a 
clinically relevant extravascular hemolysis (Risitano et al 2010b). At the moment, there is yet 
no ability to predict before starting eculizumab which patients will develop C3-mediated 
extravascular hemolysis. 
Current strategies to overcome C3-mediated extravascular hemolysis. C3 opsonization of PNH 
erythrocytes is a common phenomenon for PNH patients treated with eculizumab, even if 
the subsequent extravascular hemolysis may remain limited or well-compensated in most 
cases (Luzzatto et al 2010). However, additional therapeutic strategies are needed for 
patients developing a clinically relevant C3-mediated extravascular hemolysis, because they 
may continue to require frequent red cell transfusions, possibly developing subsequent iron 
overload (Risitano et al 2009a). We reported a patient managed by splenectomy (Risitano et 
al 2008), who achieved a substantial improvement of hemoglobin level without any medical 
complication; however, many physicians raise the concern that this approach may carry an 
increased life-long risk of infections (Brodsky 2009). In addition, the risk of intra- or peri-
operatory complications (especially thrombosis, or hemorrhage in thrombocytopenic 
patients) might also argue against this therapeutic option. Very recently a group reported a 
single case where steroids were beneficial in controlling C3-mediated extravascular 
hemolysis (Berzuini et al 2010). To best of our knowledge, this observation has not been 
confirmed in a larger series, and the well known side effects of long-term steroid use should 
advise against the use of steroids in PNH patients on eculizumab (Risitano et al 2010b). In 
some patients, the use of recombinant erythropoietin has proven beneficial by increasing 
compensatory erythropoiesis (Hill et al 2007). 
A look into the future of complement inhibition. The emergence of experimental and clinical 
evidence for CAP-initiated and C3 fragment-mediated extravascular hemolysis suggests 
that new treatment strategies appropriately targeting the early phases of the complement 
cascade should be assessed. The ideal agent should prevent the early phase of complement 
activation on PNH cells and defuse the amplification mechanisms (e.g., the CAP 
amplification loop). A systemic blockade of C3 activation through all pathways by 
monoclonal antibodies (similar to the anti-C5 eculizumab) could be considered (e.g., by anti-
C3 monoclonal antobiìodies) (Lindorfer et al 2010); however this approach may carry the 
risk of infectious and autoimmune complications secondary to a complete switching off of 
the complement system at this point. A novel candidate agent has been designed by creating 
a recombinant fusion protein between two endogenous complement-related proteins, 
complement factor H (FH) and complement receptor 2 (CR2). FH is a physiological 
complement inhibitor that modulates the initial CAP activation in the fluid phase by 
preventing C3 convertase activity and by promoting C3b inactivation into iC3b (Whaley et  
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al 1976). Indeed, FH defuses the CAP amplification loop, and it has been demonstrated 
protective from lysis for PNH erythrocytes in vitro (Ferreira & Pangburn 2007). In the aim to 
deliver FH activity locally at the site of complement activation, FH was fused with the 
iC3b/C3d-binding domain of CR2. The resulting CR2-FH fusion protein has shown a 
dramatic inhibition of hemolysis of PNH erythrocytes in vitro (Risitano et al 2009c), and 
further investigations are currently under way. A phase I clinical trial has just started to 
enroll PNH patients (Alexion Pharmaceuticals, personal communication). Once these or 
other next generation complement inhibitors proceed to clinical development, then we can 
determine whether such targeted inhibition should be additional or alternative to 
eculizumab. Indeed, the adequate control of C3, or both C3 and C5 activation on PNH red 
cells might make the downstream blockade by eculizumab redundant.  
8.3 Hematopoietic stem cell transplantation 
Cell therapy (insertion of molecules on the outer surface of blood cells) (Hill et al 2006a) and 
gene therapy (insertion of a functional PIG-A gene in early hematopoietic progenitors) have 
been hypothesized in the past as a curative approach for PNH. However, they seem 
unfeasible or even inappropriate; in fact, if the escape theory is correct, the gene therapy 
approach may not result in clinical benefit in PNH, since a repair of the damaged cell should 
result in cell destruction, as is believed to occur for normal hematopoiesis in PNH patients. 
The only curative strategy for PNH is allogeneic hematopoietic stem cell transplantation 
(SCT); SCT has been exploited since the late ’80, and has proven effective in eradicating the 
abnormal PNH clone possibly leading to definitive cure of PNH, even if morbidity and 
mortality remain a major limitation. Most reports in the literature refer to single cases or 
small series from single-institutions (Bemba et al 1999, Raiola et al 2000; Saso et al 1999), 
while large prospective studies are lacking. In an overview, Parker et al (Parker et al 2005) 
collected data from 67 patients transplanted from different types of donors (syngeneic, 
sibling or HLA-identical unrelated) and using different types of conditioning (myeloablative 
or reduced-intensity). The results from the entire group showed a 75% long-term survival, 
which is quite higher than that reported in individual series (55-100%), likely as a result of a 
reporting bias. Data from two large registry studies are also available. The International 
Bone Marrow Transplant Registry reported 57 consecutive SCT performed for PNH (16 
AA/PNH) between 1978 and 1995 (Matos-Fernandez et al 2009), showing a 2-year survival 
of 56% in 48 HLA-identical sibling transplants (the median follow-up was 44 months). The 
incidence of grade II or more severe acute GvHD was 34%, and that of chronic GvHD of 
33%; graft failure (n=7) and infections (n=3) were the most common causes of treatment 
failure. An other retrospective study from the Italian Transplant Group (GITMO) on 26 PNH 
patients (4 AA/PNH) transplanted between 1998 and 2006 showed a 57& survival rate at 10 
years. Acute and chronic GvHD were 42% (grade III-IV 12%) and 50% (extensive 16%), 
respectively (Santarone et al 2010). Given these results, guidelines for SCT in PNH are hard 
to define; the most difficult task today is to identify PNH patients who could benefit from 
HSCT (Brodsly 2010). At the moment, the main indication for SCT in PNH patients is an 
underlying bone marrow failure; as for AA patients, SCT may be performed as first-line 
therapy in the presence of an HLA-identical sibling donor, or in case of treatment failure in 
patients with an HLA-matched unrelated donor (Risitano 2011). The patient’s age largely 
drives the choice of treatment, given that transplant-related mortality and morbidity 
increase with age. Refractoriness to transfusions and life-threatening thrombosis were also  
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indications to SCT in the past, but nowadays they rather represent indications to anti-
complement treatment, with the exception of Countries where eculizumab is not available 
(yet). However, SCT remains a worthy second-line therapy for the few patients not 
achieving a good response to eculizumab. As for AA, SCT (regardless of the type of donor, 
sibling or unrelated donor) is the treatment of choice for PNH patients developing a clonal 
evolution to MDS or even AML. The Working Party for Severe Aplastic Anemia of the 
European Bone Marrow Transplantation Group, together with the French PNH Registry, are 
currently running a retrospective studies comparing the outcome of all BMT performed in 
Europe with the natural history of PNH (in the pre-eculizumab era). Likely the results from 
this study will guide future treatment strategies for PNH patients, according to specific 
disease presentation and complications. A number of questions remain open in the setting of 
SCT for PNH, to improve the clinical outcome: the most relevant is the choice of the 
conditioning regimen. Based on available data, AA/PNH patients should be treated as non-
PNH AA patients; thus, the conditioning should be cyclophosphamide/ATG for sibling 
transplants, and fludarabine-based RIC for unrelated transplants (to be performed as in case 
of failure of IST) (Bacigalupo et al 2010). In contrast, classic, non-hypoplastic, PNH patients 
receiving SCT should benefit from myeloablative conditioning (e.g., busulphan-based) 
(Raiola et al 2000); however, RIC regimens (fludarabine-based) (Takahashi et al 2004) may 
be appropriate for patients who are older or who present with relevant comorbidities.  
9. Conclusion 
PNH has attracted the efforts of several generations of investigators in the last three decades 
for its biological and clinical uniqueness. While the ’80s unraveled the GPI-anchor and the 
functional defect of the PNH clone, and the ’90s revealed the PIG-A gene and its role in the 
pathophysiology of the disease, this new century brought forth innovative therapeutic 
approaches. Thanks to current treatment options, we are finally able to change the natural 
history of PNH, possibly giving back to PNH patients a normal-like life expectancy, in 
addition to a significant reduction of disease manifestations and improvement in their quality 
of life. As often occurs in medicine, thanks to these novel treatments we are also improving 
our biological knowledge of the disease and of current treatments. Thus, the scientific 
community has already accepted the next challenge: utilize these recent insights to develop 
novel targeted treatment strategies, for further improvement of current management of PNH 
patients. 
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